



Department of Medical Oncology 2024 Annual Report

Letter from the Chair:

I want to thank everyone for an amazing and productive year! We had some very big events in 2024, and the Department of Medical Oncology has undergone tremendous changes and growth, which has reinvigorated the faculty, staff, and patients. On May 25th, 2023, the written portion of our NCI Grant was submitted, then on August 24th, 2023, we had our site visit. There were a lot of hours and effort put into our submission, and on April 18th, 2024, it was announced that we had earned our NCI Comprehensive status. A great accomplishment and a tremendous Team effort. Moreover, we moved into our new clinical space at the Honickman Center on May 20, 2024. Again, another huge undertaking that this department did together.



We also had a few losses to our TJU Family with the passing of Dr. Edith Mitchell on January 21, 2024, and Dr. Michael Mastrangelo on December 6, 2024. Both losses will be felt for many years to come, and we all have fond memories of our amazing colleagues who have shaped many careers at Jefferson and beyond.

The Department continues to work closely with Dr. Andrew Chapman, the Director of Sidney Kimmel Comprehensive Cancer Center (SKCCC) and Enterprise Vice President of Cancer Research and Oncology Services, Cancer Service Line Leadership under Dr. Maysa Abu-Khalaf, and other Jefferson Enterprise leadership to achieve the SKCC strategic plan and grow the department. We continue to streamline the department's administrative structure, created a New Division of Transplant and Cellular Therapy with Dr. Usama Gergis as the inaugural director; and continued our growth with the recruitment of 14 new faculty into Medical Oncology throughout the Enterprise over the past year. Dr. Hoda Badr from Baylor University will also be joining the faculty to fill the new dual role of Director of Population Science in the Department and the Associate Director of Population Science in the SKCCC. We have also welcomed the medical oncology faculty and staff from the Lehigh Valley Health Network (LVHN) and the Topper Cancer Center into the department. Dr. Gergis and his team have worked closely with LVHN to further develop and lead their Transplant and Cellular Therapy program at LVHN. In just a short time, they were able to bring the first Cellular therapies to the Leigh Valley regions and continue to expand the Transplant Cellular therapy footprint in the Leigh Valley region, an incredible accomplishment, and we look forward to continued integration and collaboration on multiple levels with our colleagues at LHVN.

To improve horizontal and vertical integration of Medical Oncology across the Enterprise, we continue to develop Clinical, Research, and Education, which supports an inclusive environment. A dedicated and talented administrative core, a dynamic, supportive oncology program, and a robust philanthropic and extramural funding base support these pillars. Under the leadership of Dr. Joanne Flicko-O'Hara, we will be having our first Enterprise-wide wide Educational\Research Symposium in the Fall of 2025 and then continue the symposiums on a bi-annual basis to ensure we are updated on the most current therapies and research studies, but also to enhance collaborations between all sites.

The Department has continued growth in patient visits, increased the number of chemotherapy infusions, set an all-time high of BMT/CAR-T procedures, awarded 8 million dollars in total costs from

externally funded research, robust clinical trial accrual, and have continued to train the next generation of physicians. Critical to the success of the Department of Medical Oncology, the SKCCC, and Jefferson Enterprise is the continued growth of Medical Oncology at Jefferson Northeast, Jefferson New Jersey, Jefferson Abington Hospital, and Asplundh Cancer Center, and Jefferson Einstein. We have seen the number of faculty, patients, education opportunities, community outreach, and research opportunities grow at each location.

This year-end report represents accomplishments and much more that we, as a department, have achieved over the past year. This could only be accomplished through the dedicated faculty and staff in the department and the support we have received from the College, Cancer Center, and Enterprise. Our momentum will continue in 2025, and we look forward to bringing Oncology care to a new level in the Honickman Center and other new facilities in the enterprise, continuing to grow the medical oncology faculty and staff to fill the clinical, research, and education mission and providing the cutting edge clinical care and research to patients we serve.

Thank you for the opportunity to lead the Department of Medical Oncology. I cannot wait to see what we can accomplish in 2025!

Sincerely,



Wm. Kevin Kelly, DO



In Memoriam



Edith P. Mitchell, MD
MACP, FCCP, FRCP (London)



November 20, 1948 – January 21, 2024

Dr. Michael Joseph Mastrangelo



October 3, 1938 - December 6, 2024

Department Overview

The Department of Medical Oncology was formed in 2008 and has grown significantly in the past 17 years to be one of the most diverse and integrative Departments in Jefferson Enterprise. It has the breadth and depth across the enterprise to provide high-quality oncologic care to a diverse population of patients; it provides cutting-edge research that brings national prominence to Jefferson and trains the next generation of clinicians and specialists in Medical Oncology. We continue to be a highly productive department and contribute to the overall academic mission of the SKCCC and the Institution.



- APR 18, 2024
- National Cancer Institute Designates Jefferson's Sidney Kimmel Cancer Center as a Comprehensive Cancer Center
- As part of the Sidney Kimmel Cancer Center Research Consortium, Thomas Jefferson University and Drexel University have partnered to transform breakthrough research into life-changing cancer treatments
- PHILADELPHIA, April 18, 2024 — Today, Jefferson announced that its Sidney Kimmel Cancer Center (SKCC) has earned a National Cancer Institute (NCI)
- "Comprehensive" Cancer Center designation, the highest recognition awarded by the NCI.



155
publications, 13%
increase over 2023




13

New grants



577 interventional accruals
243 non-interventional accruals

Early Phase MDG Year to Date



86

Phase I trial
Accruals


Dr. Wm. Kevin Kelly was appointed Chair to Medical Oncology in January of 2023 and has oversight of the all the Department's faculty and functions and works closely with Dr. Andrew Chapman, the Director, Sidney Kimmel Comprehensive Cancer Center (SKCCC) and Enterprise Vice President of Cancer Research and Oncology Services to achieve the SKCC strategic plans. In addition, Dr. Kelly is supported by the Department of Medical Oncology Vice Chair, Dr. William Tester, the Department of Medical Oncology Administrator and Assistant Vice President of SKCCC Operations, Janene Palidora, the Chief of Oncology Cancer Services, Dr. Maysa Abu-Khalaf, and Alex Khariton, who serves as the Chief Operating Officer of the SKCCC.

The Department has several service sites, including Jefferson Center City, Jefferson Northeast, Jefferson Bucks County, Jefferson Asplundh/Abington Cancer Center, Jefferson New Jersey (Cherry Hill and Sewell office locations), Jefferson-Einstein Philadelphia, and Jefferson-Einstein Montgomery. A Vice-Chair leads each of the sites outside of the Center City location in the Department of Medical Oncology, who has the clinical, research, and educational oversight of the location and works collaboratively with other sites. The Jefferson Center City campus is the main academic hub in the Department. It is divided into five divisions: the Division of Solid Tumor Oncology, the Division of Hematologic Malignancies, the Division of Bone Marrow Transplant (BMT) and Cellular Therapy, the Division of Population Science, and the Division of Supportive Oncology. It is unique that Population Science is embedded within Medical Oncology but provides significant research opportunities to the faculty and offers many collaborative opportunities. In addition, the Supportive Oncology Division oversees palliative care across the enterprise to all sites for all oncology patients. Still, this Division houses all the social services

for cancer patients for the Cancer Service line and has faculty that provide cancer rehabilitation services and psycho-oncology support.

The Department has two Medical Oncology/Hematology fellowship programs associated with the Department; one is on the main academic campus in collaboration with the Division of Hematology in the Department of Medicine, and the other is associated with the Einstein Department of Medicine. While these are separate fellowship programs, there is significant collaboration and opportunities for fellows to have training at all Oncology sites in the Enterprise, giving the fellows the breadth and depth of hematology and oncology experience.


The department strives to be a diverse and inclusive environment, encouraging representation and participation of people of different genders, races, ethnicities, religions, ages, sexual orientations, disabilities, and classes. The Diversity, Equity, and Inclusion Committee helps promote this diverse and inclusive environment by reviewing departmental policies and procedures, ensuring a diverse pool of faculty candidates is vetted, and continually recommending how to improve the inclusiveness and belonging in the Department. The department has a Faculty Affairs Committee that promotes the best practices for mentoring and a work environment to facilitate faculty success at all career levels. This committee also promotes work/life balance for the faculty and monitors the status of faculty development, mentoring, diversity, and equity.



Diversity, Equity, and Inclusion in Action - Across the enterprise, the Department of Medical Oncology is comprised of 57% female and 43% male gender ratio in addition to a diverse and balanced ethnic makeup.

Faculty Overview

The Department of Medical Oncology has 66 faculty members across the enterprise, with 22 professors, 12 Associate Professors, 27 Assistant Professors, and 6 Instructors. The Department of Medical Oncology includes 30 Jefferson Community Physicians who do not hold faculty appointments.



Full faculty list with rank and track

Professor's					
Name		Track		Name	Track
Amy Elizabeth Leader		Research Excellence		Margaret T. Kasner	Clinical Scholar
AnaMaria Lopez		Clinical Scholar		Maysa Abu-Khalaf	Clinical Scholar
Andrew E. Chapman		Clinical Scholar		Pierluigi Porcu	Tenure Status
Daniel Silver		Tenure Status		Rita S. Axelrod	Clinical Scholar
Grace Lu Yao		Tenure Status		Ronald E. Myers	Tenure Status
Hee-Soon Juon		Tenure Track		Takami Sato	Clinical Scholar
Hushan Yang		Tenure Track		Ubaldo Martinez Outschoorn	Clinical Scholar
Joanne Filicko-O'Hara		Clinical Scholar		Usama Gergis	Clinical Scholar
Kuang-Yi Wen		Tenure Track		William J. Tester	Clinical Educator
Madhavan Velayudhan Pillai		Clinical Educator		William K. Kelly	Clinical Scholar
Marcia Brose		Clinical Scholar			
Associate Professor's					
Name		Track		Name	Track
Adam Binder		Clinical Scholar		Jennifer M. Johnson	Clinical Scholar
Anjali Mishra		Tenure Track		Lewis J. Rose	Clinical Educator
Atrayee Basu Mallick		Clinical Educator		Marlana M. Orloff	Clinical Scholar
Babar Bashir		Clinical Scholar		Sarah Gordon	Clinical Scholar
Brooke Worster		Clinical Scholar		Seyfettin Onder Alpdogan	Clinical Scholar
Christopher M. McNair		Research Excellence			
Assistant Professor's					
Name		Track		Name	Track
Allison M. Zibelli		Clinical Educator		Maria Hafez	Clinical Scholar
Avnish K. Bhatia		Clinical Educator		Michael J. Ramirez	Clinical Educator
Beatrice Razzo		Clinical Scholar		Michael Wysota	Clinical Scholar
Chetan Jeurkar		Clinical Scholar		Mizue Tera	Research Excellence
Chun Wang		Research Excellence		Munjireen Sifat	Tenure Track
Daniel Lin		Clinical Scholar		Nitin Chakravarti	Research Excellence
Elizabeth R. Collins		Clinical Scholar		Patrick Johnston Mille	Clinical Educator
Emma N. Weaver		Clinical Educator		Rachael Grosso	Clinical Educator
Evan Nardone		Clinical Educator		Rajan Singla	Clinical Educator
Frederick M. Fellin		Clinical Educator		Rino S. Seedor	Clinical Scholar
Gina Marie Keiffer		Tenure Track		Steven Manobianco	Clinical Scholar
Ida Micaily		Clinical Scholar		Suchit Bhutani	Clinical Educator
Kevin Zarrabi		Clinical Scholar		Xia Bi	Clinical Scholar
Lindsay Wilde		Clinical Scholar			
Instructors					
Name		Track		Name	Track
Allison Gradone		Clinical Educator		Irina A. Vasilevskaya	Research Excellence
Arpona Dev Nath		Clinical Educator		Jiahui Jiang	Clinical Educator
Boula Gattas		Clinical Educator		Nikita Nikita	Research Excellence


Jefferson Community Physicians who do not hold faculty appointments

Jefferson Community Physicians (JCP)			
Name	Enterprise Practice Location	Name	Enterprise Practice Location
Amy Mackenzie	Jefferson Asplundh	Rakesh Biswas	Jefferson Northeast
Ankur Parikh	Jefferson Asplundh	Vladimir Limonnik	Jefferson Northeast
Avnish Bhatia	Jefferson Asplundh	Andres Ferber	Jefferson New Jersey
Christian (CJ) Fidler	Jefferson Asplundh	Andrew Iksander	Jefferson New Jersey
Elham Siddiqui	Jefferson Asplundh	Anthony Scarpaci	Jefferson New Jersey
Frederick M. Fellin	Jefferson Asplundh	Aziz Nazha	Jefferson New Jersey
Joanna Rodriguez	Jefferson Asplundh	Eduardo Fernandez	Jefferson New Jersey
Kevin Hou	Jefferson Asplundh	Michael Rotkowitz	Jefferson New Jersey
Melanie Nordlinger	Jefferson Asplundh	Steven Borson	Jefferson New Jersey
Pooja Suresh	Jefferson Asplundh	Yvonne Dansoa	Jefferson New Jersey
Sheel Patel	Jefferson Asplundh	Zachary French	Jefferson New Jersey
Steven Cohen	Jefferson Asplundh	Alankrita Taneja	Jefferson Einstein Philadelphia
Willard Andrews	Jefferson Asplundh	Claudia Dourado	Jefferson Einstein Philadelphia
Andres Ferber	Jefferson Northeast	Gabor Varadi	Jefferson Einstein Philadelphia
Byron Lu	Jefferson Northeast	John Leighton Jr	Jefferson Einstein Philadelphia
Jeffrey Stevens	Jefferson Northeast	Ryan Mayo	Jefferson Einstein Philadelphia
Jennifer Hong	Jefferson Northeast	Zachary Cohn	Jefferson Einstein Philadelphia
Kathleen (Casey) Degen	Jefferson Northeast	Byron Lu	Jefferson Einstein Montgomery
Lewis J. Rose	Jefferson Northeast	Felice LePar	Jefferson Einstein Montgomery
Max Geisinger	Jefferson Northeast	Mark Morginstin	Jefferson Einstein Montgomery
Patrick Lynch	Jefferson Northeast	Minal Dhamankar	Jefferson Einstein Montgomery
Raghava Levaka Veera	Jefferson Northeast	Mitchell Goldstein	Jefferson Einstein Montgomery
Rajan Singla	Jefferson Northeast	Tracey Evans	Jefferson Einstein Montgomery

Advanced Practice Clinicians (APC's) at all sites – Includes Same Day Next Day (SDND) Care Team

Advanced Practice Clinicians (APC's)			
Name	Enterprise Practice Location	Name	Enterprise Practice Location
Amanda Jackson	Jefferson Center City	Meghan Coleman	Jefferson Asplundh
Carol Gung	Jefferson Center City	Sarah Daniels	Jefferson Asplundh
Cynthia Wheeler	Jefferson Center City	Karon Martyn	Jefferson Asplundh
Emily Matey	Jefferson Center City	Vadim Selyukov	Jefferson Asplundh
Erin Sharpe-Mills	Jefferson Center City	Aileen Owens	Jefferson Asplundh
Helen Evers-Hunt	Jefferson Center City	Dana Liskova	Jefferson Asplundh
Janice Carsello	Jefferson Center City	Amy Young	Jefferson Northeast
Jessi Falcone	Jefferson Center City	Elizabeth Thorton	Jefferson Northeast
Kaitlin Rancani	Jefferson Center City	Christian Price	Jefferson Northeast
Kaitlyn Smith	Jefferson Center City	Nicole Penko	Jefferson Northeast
Kathryn Yingling	Jefferson Center City	Rachel Weeks	Jefferson Northeast
Lisa Kearns	Jefferson Center City	Lori Napravnik	Jefferson New Jersey
Madeleine Naccarato	Jefferson Center City	Johanna Cruz	Jefferson New Jersey
Marleah Dimenna	Jefferson Center City	Amber DeLeece	Jefferson New Jersey
Mercy George	Jefferson Center City	Latifah Nelson	Jefferson New Jersey
Miranda Tsang	Jefferson Center City	Margaret O'Neill	Jefferson New Jersey
Pashara Arties	Jefferson Center City	Courtney McAlly	Jefferson New Jersey
		Ashley Yonks	Jefferson Einstein Montgomery

Same Day Next Day Advanced Practice Clinicians (APC's)			
Name	Enterprise Practice Location		
Amy Klarman	Jefferson Enterprise		
Courtney Scott	Jefferson Enterprise		
Tintu George	Jefferson Enterprise		
Mea Moore	SDND Patient Care Coordinator		



Jefferson Health Department of Medical Oncology brings together a team of cancer experts from every specialty to provide our patients with truly holistic care for all types of cancer, from evaluation to treatment and recovery. As part of Sidney Kimmel Comprehensive Cancer Center (SKCCC), we're proud to offer nationally recognized cancer care right here in the Greater Philadelphia area and Southern New Jersey. In 2024, twenty-eight department faculty were recognized as *Philadelphia Magazine's* "Top Doctors of 2024", a prestigious honor and acknowledgement for the department's faculty across the enterprise.



Department of Medical Oncology Productivity

Clinical Accomplishments

**Einstein Philadelphia and Einstein Montgomery use a separate reporting system, and select data is not available.*

The Department of Medical Oncology had a very successful year across the enterprise in 2024. The Clinical Pillar of Operations successfully attained the following clinical achievements across all enterprise locations: adoption of unified chemotherapy consent form, development of "Same Day/Next Day" cancer care access, assessment of pain score and plan for every patient, standardized documentation of performance status and depression screening, standardized documentation of team-based care, standardization of post discharge follow-up, consistent pregnancy assessment for all women of childbearing potential before starting chemotherapy, Oral chemotherapy teaching and assessments.

Establishment of Same Day/Next Day Cancer Initiative

Jefferson's Same Day/Next Day Cancer care offers newly diagnosed patients a telehealth appointment with an oncology clinician in 48 hours or less. Our experienced clinicians are part of the cancer team and work closely with the doctors at the Sidney Kimmel Comprehensive Cancer Center

Same Day/Next Day Cancer care can assist with referring physician with the following services:

- Evaluation of suspicious findings and expedited care through our Diagnostic Oncology Program
- Schedule additional testing based on National Comprehensive Cancer Network guidelines and instructions provided by the Sidney Kimmel Comprehensive Cancer Center disease-specific teams, with oversight and care review by an oncologist
- Provide emotional support and facilitate transition of care, including an appointment with an oncologist
- Identify the need for additional services such as genetics, social work, etc.
- Expedite physician appointments if clinical findings dictate the need for more urgent evaluation
- Ensure proper specialist appointments are arranged

SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER

Same Day/Next Day Cancer Care
Meet the Team

Avnish Bhatia, MD
Clinical Director,
Same Day/Next Day Cancer Care

Tintu George, CRNP

Courtney Scott, CRNP

Amy Karman, PA-C

To refer a patient, please call 888-305-0790.

Jefferson Health
JeffersonHealth.org/CancerCare

Have you been recently diagnosed with cancer?

We can help.

Jefferson's **Same Day/Next Day Cancer Care** offers newly diagnosed patients a telehealth appointment with an oncology clinician in **48 hours or less**.

Our experienced clinicians are part of your cancer team and work closely with the doctors at the Sidney Kimmel Comprehensive Cancer Center. They are here to offer you guidance and expedited support that includes:

- Assistance in scheduling appointments with physicians or specialists
- Ordering additional testing when needed
- Answering your questions, easing your concerns and helping you with next steps
- Accessing and organizing your medical records for future appointments
- Connecting you with trusted resources, programs and support groups
- Preparing you for your specialist appointment

Telehealth appointments are available:

Monday to Friday – 8 a.m. to 8 p.m.
Saturday – 8 a.m. to 12 p.m.

Call 1-888-305-0790 to schedule your appointment or
schedule online at JeffersonHealth.org/CancerCare.


Jefferson's Same Day/Next Day Cancer care offers newly diagnosed patients a telehealth appointment with an oncology clinician in 48 hours or less. Our experienced clinicians are part of the cancer team and work closely with the doctors at the Sidney Kimmel Comprehensive Cancer Center

CAR T and BMT Program

Usama Gergis, MD., MBA

Division Director, Transplant and Cellular Therapy / Bone Marrow Transplant Division

The Transplant and Cellular Therapy program is led by Usama Gergis, MD, MBA, with support from Mike Dugan, MBA. In 2024, the team initiated integration with the Transplant and Cellular Therapy (TCT) Program at Lehigh Valley Health Network, and Dr. Gergis was named Medical Director of both programs. The BMT unit had a successful year in 2024, increasing CAR-T procedures by 30% over the prior year. The program performed the first cross-departmental procedure with the Melanoma Program - a Tumor Infiltrating Lymphocyte (TIL) procedure. The Landmark Survivorship Program was established for our transplant and cellular therapy alumni. Additionally, the BMT team is accruing for 10 clinical trials, including a non-cancer trial for Stiff Person Syndrome.




November 15, 2024 LHVN / TJUH Retreat at Asplundh Cancer Center



Research Accomplishments

Grants

The Department of Medical Oncology has steadily increased externally funded research expenditures year over year for the past ten fiscal years.




Publications

Medical Oncology faculty members authored 155 publications from January 1, 2024, to December 31, 2024. In the past year, 26 publications were intra-departmental collaborations. On average, our faculty publications had an impact factor of 14, with 22 publications having an impact factor greater than 10. For a full list of publications, see Appendix A.

Over the past three years, our department has published 518 publications, with 134 publications being intra-departmental collaborations. Over three years, our publications had an impact factor of 11.59, with 23% having an impact factor greater than 10.

There were 155 publications authored by Medical Oncology Faculty Members from 1/1/24 to 12/31/24. 26 publications (16.77%) were intra-departmental collaborations.

Omitting Journals with an undefined Journal Impact Factor. 22 publications (14.57%) had a Journal Impact Factor ≥ 10 (†). 26 publications (17.22%) had a Journal Impact Factor ≥ 9 († or ‡). 51 publications (33.77%) had a Journal Impact Factor ≥ 5 († or ‡ or #). Average Journal Impact Factor [1050.3/151]:6.96.



Education Accomplishments

Education Accomplishments

Joanne E. Filicko-O'Hara, MD

Educational Pillar Lead

Associate Program Director, Hematology/ Medical Oncology Fellowship Program, TJUH

The Department of Medical Oncology has active medical education programs in Undergraduate Medical Education (UME), Graduate Medical Education (GME), and Continuing Medical Education (CME). A commitment to outstanding education that includes clinical “at the bedside” teaching, didactic conference-based learning, and research education.

UME includes (1) Phase I learning under the direction of Dr. Marlana Orloff and includes a focus on “Blood and Host Defense”; (2) Phase 2 learning in clinical clerkships with multiple faculty members covering the four Blue Medicine services throughout the year; (3) Phase 3 learning including sub internships on the Blue Medicine Services, as well as electives in solid tumor inpatient consults, outpatient electives in solid tumor and hematologic malignancies, and bone marrow transplant and cellular therapy.

Medical students also have opportunities to do clinical research with our faculty members, from learning how to submit IRB paperwork to submitting manuscripts for publication.



The department’s GME effort includes the ACGME-accredited Fellowship in Hematology and Medical Oncology. The fellowship is a joint effort with the Division of Hematology in the Department of Medicine. It is approved for up to 24 fellows, usually having 6-7 fellows per year. Most fellows pursue training in both hematology and medical oncology. Fellows do 18-24 months of clinical time, with the second half of the fellowship tailored towards career goals, including more clinical time and basic or clinical research. All fellows are required to do “scholarly

work” and are mentored by faculty to produce presentations, clinical research protocols, and manuscripts. In the last five years, 36% of fellows have gone on to academic careers, 23% have gone into general practice, 32% have chosen a hybrid between academic and general practice, and 6% have gone into the pharmaceutical industry. 23% have stayed within the Jefferson Health System.

The Hematology and Medical Oncology Fellowship program at Einstein Medical Center Philadelphia proudly accepted its first fellow in the 2014–2015 academic year. The fellowship program is a three-year ACGME-accredited, clinically oriented program that accepts two fellows annually. Jefferson Einstein Hospital and Jefferson Einstein Montgomery Hospital have extremely busy inpatient and outpatient services, allowing broad exposure to various diseases and diverse patient populations, ensuring a well-rounded learning experience. Our program has a board passing rate of 100% on the first attempt for Hematology and Medical Oncology. Fellows who graduated from our program have joined renowned academic institutions or large private practices.



We held our first Jr. Faculty Mentor Program meeting Friday, March 1, 2024. Drs. Kelly & Filicko-O'Hara interviewed Drs. Russell Schilder & Michael Mastrangelo who shared their many years of experience with our faculty 5 years & under. We can't thank them enough for all of their wisdom.

The GME effort also includes mentorship of internal medicine residents. Similar to UME, this includes clinical teaching on the Blue Medicine services, consult services, and in the Bone Marrow Transplant Unit. It includes both inpatient and outpatient experiences. Faculty provide didactic conferences and mentorship for clinical research projects.

CME is intertwined with the efforts of the Sidney Kimmel Cancer Center and includes multiple recurring conferences throughout the year. These include tumor boards, research conferences, and symposia on various cancer-related topics.



The Department of Medical Oncology faculty includes physicians at multiple enterprise sites. While the main efforts for UME and GME are based at the Center City campus, the faculty at the other sites are also heavily involved in education at all levels. There are medical students from the SKMC who rotate at the other sites and students from other local medical schools who rotate with our faculty (e.g., Cooper Medical School – Rowan University at Jefferson, New Jersey offices). There are internal medicine and family medicine residencies at Abington-Jefferson, Jefferson Northeast, Jefferson–Einstein, and Jefferson New Jersey. These residents will manage inpatients with our faculty and have the opportunity to do outpatient electives. The CME effort includes programs at the other sites, including Jefferson Northeast – SKCC Oncology Grand Rounds.

On Friday, September 14, the Department of Medical Oncology Education Pillar held a “Junior Faculty Mentoring Program”, led by Dr. Said Ibrahim, MD, MBA, MPH, Dean of The Sidney Kimmel Medical College (SKMC) and President of Jefferson University Physicians (JUP). The mentoring session was held in Bluemle from 3-5 pm with a happy hour that followed. Attendees included junior faculty, including SKMC junior faculty, and also those from around the enterprise, Advanced Practice Clinicians (APCs). The mentoring program included a presentation/ discussion, and then breakout groups where

department clinicians meet with a more senior faculty member. Dean Ibrahim discussed the following items with attendees; Vision for the next 5-10 years at Sidney Kimmel Medical College (SKMC), previous experiences from other institutions that shape Dean Ibrahim's vision for Jefferson and the SKMC, how to find a mentor and why mentors are so important in the career of a clinician, and the best/worst advice given to Dean Ibrahim by a mentor.

Friday, September 13, 2024
Dr. Said Ibrahim, MD, MBA, MPH
Dean of Sidney Kimmel Medical College (SKMC)
President of Jefferson University Physicians (JUP)
at the Medical Oncology
Jr. Faculty Mentor Program Meeting



Graduates of the Jefferson Fellowship program and the institution they joined after graduation

Class of 2020	
Kim Aderhold, DO	Hematology Oncology - Tower Health Medical Group, Reading, PA
Dan Altman, MD	Abramson Cancer Center - Chester County Hospital, West Chester, PA
William Johnson, DO	MSKCC, New York, NY
Gina Keiffer, MD	SKCC - Jefferson –Leukemia Program- CC & NJ, Philadelphia, PA
Amanda McBride, MD, PhD	Research Year → Incyte Corporation - Wilmington, DE
Maria Vershovovsky, MD	Abramson Cancer Center - Chester County Hospital, West Chester, PA
Class of 2021	
Sushil Ghimire, MD	MD Anderson Cancer Center at Cooper, Camden NJ
Kevin Hou, MD	Abington Jefferson, Abington, PA
Teresa Lee, MD, PhD	Fox Chase Cancer Center, Philadelphia, PA
Jonathan Pan, MD	MD Anderson Cancer Center at Cooper, Camden NJ
Sabarina Ramanathan, MD	Texas Oncology- Sugarland, Sugar Land, TX

Kelsey Sokol, MD	Bennett Cancer Center, Stamford CT
Class of 2022	
Xia Bi, MD	SKCC-Jefferson – Transplant & Cellular Therapy, Philadelphia, PA
Victor Bilan, MD	Hematology & Oncology Assoc - UPMC Hillman Cancer Center, Pittsburgh, PA
Ranju Kunwor, MD	St Louis University, BMT & Cellular Therapies Program, St Louis, MI
Ida Micaily, MD	SKCC Jefferson – Thoracic Oncology Program, Philadelphia, PA
Zachary Quinn, MD	Abramson Cancer Center - Chester County Hospital, West Chester, PA
Christopher Terry, MD	Sturdy Memorial Associates in Attleboro, MA
Class of 2023	
Molly Halloran, MD	Incyte Corporation - Wilmington, DE
Sarah Houtmann, MD	Abramson Cancer Center - Chester County Hospital, West Chester, PA
Yasir Khan, MD	Southern Oncology- Hematology Associates, Vineland NJ
Daniel Lefler, MD	Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Colin Thomas, MD	Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Class of 2024	
Monica Adedeji, MD	Planning academic classical hematology – taking time off
Aditya Eturi	McGlinn Cancer Institute, Reading, PA
Zachary French	SKCC – Jefferson – Cherry Hill & Sewell, NJ
Andrew Iskandar	SKCC – Jefferson – Cherry Hill & Sewell, NJ
Chetan Jeurkar	SKCC- Jefferson – Leukemia Program, Philadelphia PA
Aditya Kulkarni, MD	Cooperman Barnabas Medical Center - Robert Wood Johnson Barnabas Health System, Livingston, NJ
Shaik Abdul Samad Rashid	Frank M and Dorothea Henry Cancer Center at the Geisinger Wyoming Valley Campus, Wilkes-Barre, PA


In summary, the faculty of the Department of Medical Oncology provides a broad spectrum of educational experiences that are both clinical and non-clinical, experiential, and didactic, practical, and research-based, and encompass UME, GME, and CME.

Philanthropy and Community Engagement

Endowments

The Department of Medical Oncology has steadily increased endowments year over year for the past three years.





Philanthropic Effort

Across the enterprise, the Department of Medical Oncology has brought in an average of \$2,759,960 each year in philanthropic funds to help support academic and research initiatives. This would not have been possible without our colleagues in the Office of Institutional Advancements (OIA). With the partnership of OIA, the Department of Medical Oncology hosted several events throughout the department and community in 2024. Notable philanthropic departmental and community events include but were not limited to; the Cancer Legacy in Action Projects (CLAP) Foundation, SKCCC and Deits & Watson Community Outreach Unit ribbon cutting ceremony, Mobile Screening (Deitz & Watson) funded SKCCC Innovation Fund and second “mobile screening” vehicle, SKCCC Torresdale Food Pantry ribbon cutting ceremony on March 25th, 19th Annual Pancreatic Symposium on November 9th, Breast Cancer Symposium on November 15th, Paige S. Tibbets Legacy Wine Event on November 16th, and 7th Annual Paige Tibbets Legacy Fund, Barbara A. Colameo (BAC) Transportation Fund Casino Night on November 22nd.

Department of Medical Oncology Mission Moments of Philanthropic Effort



Seventh Annual Paige Tibbets Legacy Fund Event - \$226,536 in 2024 and \$1,000,000+ raised for young adult cancer patients





Check

Presentation with Cancer Legacy in Action Projects (CLAP Foundation): \$25,000 gift for patient support

Division and Vice Chairs Overview

Division of Medical Oncology – Center City

Division of Solid Tumor Oncology

Atrayee Basu Mallick, MD

Division Director, Solid Tumor Division



A portrait unveiling ceremony of Dr. Takami Sato, the Director of Metastatic Uveal Melanoma Program. This portrait marks Jefferson's first portrait honoring an Asian American.

The solid tumor division is comprised of 18 faculty members dedicated to academic research, clinical trials, and disease-specific clinical care. They provide outpatient and inpatient services for various types of solid tumors, including those affecting the gastrointestinal, genitourinary, head and neck, thoracic, skin (including melanoma), soft tissue, bone, gynecological, and breast areas. This division is organized into teams, each specializing in a subspecialty of solid tumors. Each team has a leader who

focuses on collaborating with basic/translational scientists and developing a clinical trial portfolio. The teams also work closely with advanced care hubs throughout the enterprise in medical oncology. The faculty members collaborate

with medical oncology from advanced care hubs, offering direct guidance and support for complicated and rare cases.

Clinical

The focal point of all activities is the provision of state-of-the-art clinical care. The service is structured in a disease-specific care team model. Besides regular medical oncology clinics, clinical care is also extended by implementing Multidisciplinary Clinics (MDC) in all subspecialties. In these clinics, patients can meet with medical oncologists, surgeons, and radiation oncologists in the same setting. This setup aims to streamline real-time multidisciplinary care, particularly in complex cases, and offers the convenience of a single visit to consult with multiple providers, with 19,482 outpatient visits being completed by the solid tumor faculty in 2024.

Research

The solid tumor faculty actively engages in a spectrum of clinical trials, encompassing investigator-initiated, cooperative group, and industry-sponsored trials spanning from Phase 1 to Phase III. Our Phase 1 trial program is distinguished nationally, with over 45 active trials at any time, including first-in-human trials in solid tumors. This has positioned us as a referral center for the tristate area. Beyond clinical research, faculty members are involved in basic and translational research. The division boasts over 13 active grants, including ROI and DOD (Department of Defense).

In the calendar year 2024, the division achieved a notable scholarly output, with 81 publications and 40 presentations at both locoregional and national levels.

Education

The faculty actively educates medical students, residents, and hematology and oncology fellows. This involvement encompasses outpatient and inpatient clinical settings, and they also deliver didactic lectures on a scheduled basis.

Community Outreach

In the previous year, the faculty has led in initiating and chairing over 15 symposiums, cancer walks, screening events, and talks within the SKCC catchment area. These events cover a range of topics related to specific cancers, diversity, inclusion, and community engagement.

Grateful Patient Spotlight: Alexander and Johnston Family



"People Should give because it feels good to give. We feel so good about our philanthropic endeavor with

Jefferson" - John and Elaine Alexander.

Division of Hematologic Malignancies and Cellular Therapy- Center City

Pierluigi Porcu, MD

Division Director, Hematologic Malignancies Division

The Division of Hematologic Malignancies (HM) and Cellular Therapy is the Department's main home for academic research activities and advanced disease-focused clinical care in blood cancers. The Division provides high-acuity inpatient care at TJUH for aggressive and complex blood cancer patients. With the recruitment of the new Division Director in late 2016, the Division was reorganized and grew from 10 to 17 faculty, including 2 PhDs. This reorganization effort transformed the Division, culturally and operationally, building a more distinct research identity, raising its academic stature, locally and nationally, and bringing new funding (from federal agencies, foundations, and industry) and philanthropic gifts. The Division promotes a culture of service, academic excellence, mentoring, respect, and inclusion for faculty and fellows and all nursing and administrative staff. In 2022 and 2023, the Division faced some clinical challenges due to the retirement of four senior clinical faculty and the departure of two clinical faculty. However, in 2024, the Division successfully recruited three new junior faculty members, addressing the clinical need gap in the Leukemia and Myeloma Sections. In addition, a new junior faculty recruit for the BMT program has signed up and will join the Division in 2025. Recruitment efforts, therefore, have been very successful in the past year.



Pictured left to right: Drs. Adam Binder, Marlana Orloff, Pierluigi Porcu, and Russel Schilder at the SKMC Faculty Awards ceremony. Dr. Pierluigi Porcu won the SKMC Career Research Award and Dr. Adam Binder won the Education Award

Division Milestones Since Last Year's Report

Clinical Service

- Recruitment of three junior clinical faculty
- Expansion and growth of the Transplant and Cellular Therapy Program to the LVHN
- Inclusion of the LVHN Oncology group in the Heme Malignancies Tumor Board
- Growth of the international Hereditary Heme Malignancy Tumor Board (Dr. Keiffer)

Research/Academic

- Dr. Kasner appointed Associate Director for Clinical Research, SKCCC
- Dr. Kasner, co-chair of the ABIM Longitudinal Knowledge Assessment Approval Committee
- Dr. Kasner key faculty mentor for R25 entitled AACI-CRI Clinical Trial Concept Workshop.
- Dr. Kasner appointed co-Chair of the ASH CME accreditation committee
- Dr. Martinez Outschoorn named Chair of the Cancer Biology Study Section of the NCI
- Dr. Wysota (new faculty) joined the HIV and Cancer Working Group

- NCI R01 (Dr. Mishra)
- ONO Sponsored Research Contract (Dr. Mishra)
- Robert Winn CDA (Dr. Bi)
- 2024 Incyte Ingenuity Award in GVHD (Dr. Bi)
- SKCC Barnett Memorial Award for Early Career Clinical Investigators (Dr. Bi)
- Multiple publications and Career Development Awards submitted
- Dr. Gergis promoted to Division Director
- SKCCC Pilot Award on HIV and Cancer (Dr. Porcu)
- COE Office Pilot Award on HTLV-1 (Dr. Porcu)
- Division faculty invited to give talks at conferences at the national and international level.

Education and Mentoring

- Dr. Wilde assumed leadership of the Fellowship Program, appointed new Associate Directors
- Hematologic Malignancies Lecture Series Plan revised
- Trainees' accomplishments (Dr. Ratkowitz: ASH Quality Improvement Institute)
- High number of TJU house staff applying for the Fellowship program

Community Outreach and Engagement

- Division faculty members of the IRT program were at the forefront of extremely productive COE efforts over the past 12 months.
- These efforts were recognized at the SKCCC retreat, with a COE award to the IRT Program.

Future Plans

The Division is planning further growth over the next year, within the budgetary limits available, remaining focused on the strategic goals set by the Director. The Division successfully replaced lost faculty positions in HM in 2024 and recently signed up a new faculty member in SCT/CART in the center city that will start in July 2025. This will support the expansion of the TCT program to include the Lehigh Valley. The Division remains focused on the recruitment of senior faculty for the Myeloma Section and Lymphoma Section lead roles. Finally, the Division will continue to expand collaborative research in blood cancer through the BCCE.


Division of Supportive Oncology

Brooke Worster, MD

Division Director, Supportive Oncology

Division of Supportive Oncology 2024

Supportive Oncology describes an inter-professional team focused on supporting the whole person and their caregivers regarding the various effects of cancer, including physical, emotional, functional, and spiritual. This care is delivered from diagnosis through survivorship, living with long-term disease and end-of-life. Our division includes pain and symptom management, palliative medicine, supportive counseling, nutritional guidance, cancer rehabilitation, addressing financial toxicity associated with medical care, patient support and education, advanced care planning, and assistance with complex



medical decision-making. All these elements are critical to a successful patient outcome and core to SKCC's focus on patient-centered cancer care - treating the whole person. The inter-professional division includes physicians, nurse practitioners, psychiatrists, licensed clinical social workers, nurses, financial advocates, nutritionists, and a large research team that collaborates with population health, family medicine, and emergency medicine as well as the Center for Connected Care. Within the Division are training programs for all disciplines.

The Division of Supportive Oncology assists thousands of cancer patients, caregivers, and families yearly at the Sidney Kimmel Cancer Center (SKCC). In FY24, over 10,000 unique patients relied on supportive services offered during the course of cancer treatment and survivorship.

Supportive Oncology 2024 Highlights:

Transitioned from Distress Screening to Health-Related Social Needs Screening. This has enabled our teams to better understand and address challenges that can be barriers to care and functioning. Successful transition to The Honickman Center, inclusive of The Cancer Support and Welcome Center. In the coming months, we will open The Image Recovery Center to assist patients with wig and prosthesis fittings, head shaving, scarves, and head coverings, as well as various other services over time.


Our partnership with Independence Blue Cross (IBC) using home visits for our most vulnerable patients has made over 300 multi-disciplinary home visits and actively follows over 100 patients. We have also collaborated with Population Health to explore other value-based reimbursement opportunities. We added a full-time palliative care physician and RN to Asplundh. Their clinic is reaching capacity within one year of opening. We are planning to add an Advanced Practice Clinician (APC) and a MSW in the coming year. We welcomed our first full-time psychiatrist to our team. Her work is focused on creating timely access to psychiatric care during treatment for our patients.

Oncology Social Workers have seen nearly 3 times as many patients as the prior year and continue to provide billable counseling services to interested patients.

The Cancer Support and Welcome Center has offered close to 100 patient programs and has doubled drop-in volume since moving to The Honickman Center. Additionally, a new, patient-centric program registration portal will launch at the beginning of 2025 to simplify program registration. This was the culmination of a 2-year effort to develop such a platform, which was entirely externally funded. Oncology Nutrition doubled its patient reach over the past year and added another Dietitian in Center City and New Jersey. They have seen over 2,200 patients with over 10,300 outreaches. Additionally, they provide classes through the Welcome Center, including a 6-week cooking class for cancer survivors in conjunction with The Vetri Cooking Kitchen.

In collaboration with the Office of Institutional Advancement, we have raised over \$320,000 in philanthropy to support various patient and caregiver needs. Additionally, we have received over \$100,000 from the American Cancer Society to support transportation and lodging.

Financial Advocacy has enabled \$8.1 million to be recaptured through free drug and drug replacement programs, at \$956,000, posted directly to patients' accounts. They assisted over 4,507 patients.



The Division has been engaged with SKCCC leadership and created a 5-year business plan to expand Supportive Oncology across the Enterprise. Asplundh was successfully rolled out, and Torresdale will be starting in the first quarter of 2025. Conversations are ongoing with Jefferson, New Jersey, and Einstein.

An innovative partnership with Independence Blue Cross (IBC), which began on August 1, 2023, is ongoing and will leverage the Supportive Oncology team to offer supportive services in the home. The pilot aims to demonstrate the impact that Supportive Oncology services have on patient outcomes and cost of care, and utilization. Historically, many of these clinical offerings are non-reimbursable under fee-for-service billing. IBC is engaged with Jefferson Population Health and is contracting to discuss future bundled payments to reimburse for these services.



Additionally, we have a successful research team that collaborates on federal and foundation grants with the Division of Population Health within SKCC, the Department of Family and Community Medicine, and the Department of Emergency Medicine, as well as the Center for Connected Care. Outside collaborators on two of Dr. Worster's grants from 2023 (U01, R01) are: The University of Pennsylvania, State University of New York at Buffalo, and Oregon Health and Sciences University. The Supportive Oncology team has had numerous publications and conference presentations over the past year, with several papers in the press currently.

Attended Barbara A. Colameco Cancer Transportation Fund Casino Night

Our priority for the coming year will be expanding Supportive Oncology Services per the business plan and continuing to explore value-based contracting opportunities with Jefferson Health Plan and other payors.

Our program continues to be the most robust of its kind in the region and has impacted tens of thousands of patients and their caregivers since its inception.

Division of Population Science

Introduction and Overview

The Division of Population Science within the Department of Medical Oncology at Thomas Jefferson University continues to serve as a hub for interdisciplinary, community-engaged cancer research. Established in 2008, our division's overarching mission is to improve cancer prevention, early detection, treatment outcomes, and patient-centered care, while striving to eliminate disparities and advance health equity. We achieve these goals through a diverse portfolio of research themes and strategies, encompassing biomarker discovery, precision oncology, behavioral intervention development, digital

health, and the implementation of evidence-based cancer prevention and control measures in clinical and community settings.

By fostering research partnerships within the Division, the Department, the Sidney Kimmel Comprehensive Cancer Center (SKCCC), and the broader health system, we accelerate the translation of scientific findings into actionable solutions. Our work is driven by a commitment to developing culturally and contextually appropriate interventions, improving health communication, and refining decision-making processes along the cancer care continuum—from prevention and screening to survivorship. The Division’s influence extends beyond traditional academic boundaries, engaging community organizations and stakeholders to ensure that discoveries lead to meaningful improvements in population health.

Discovering Cancer Markers, Mechanisms of Response, and Models of Cancer Etiology: Focuses on identifying biological markers, understanding cancer response mechanisms, and modeling cancer development.	Decision-Making, Behavior, and Lifestyle Change Examines how decisions, behaviors, and lifestyle modifications impact cancer prevention and control.	Community and Environmental Effects on Health and Well-being: Investigates how community dynamics and environmental factors influence health outcomes and cancer control.
<ul style="list-style-type: none"> • Breast Cancer <ul style="list-style-type: none"> • A Population-based Approach to Single CTC Analysis in Metastatic Breast Cancer Outcomes • Prostate Cancer: <ul style="list-style-type: none"> • Genomic Differences and Clinical Implications of DNA Methylomes Between Single and Clustered CTCs in Patients with Metastatic Castration-resistant Prostate Cancer • Single-cell Genomic Analysis of CT in the Clinical Outcome of Metastatic Prostate Cancer • Liver Cancer: <ul style="list-style-type: none"> • Bio-Psycho-Social Drivers of Disparities in Liver Disease Progression among Korean Americans with Hepatitis B Infection • Other: <ul style="list-style-type: none"> • Identifying Predictive, Prognostic, and Race-specific Molecular Biomarkers for Early Detection and Treatment Outcomes of Solid Tumors (Chun Wang's research) • Studies to Identify Genomic Biomarkers Using Liquid Biopsy-based Approaches (Hushan Yang's research) 	<ul style="list-style-type: none"> • Breast Cancer: <ul style="list-style-type: none"> • A Mobile Txt-based Intervention to Improve Adherence to AHT and Symptom Management for Breast Cancer Survivors • Cervical Cancer: <ul style="list-style-type: none"> • Hashtag HPV: Engaging Parents through Social Media to Increase HPV Vaccination • Chronic Myeloid Leukemia: <ul style="list-style-type: none"> • TKI Adherence among CML Patients • Prostate Cancer: <ul style="list-style-type: none"> • Peer-Based Intervention for Genetic Evaluation among African American Men • Other: <ul style="list-style-type: none"> • Mindfulness to Support Focus: A Proactive Approach to Prevent Chemo-Brain • Music Therapy vs. Cognitive-Behavioral Therapy for Cancer-related Anxiety (MELODY) • Improving SDM and Lung Cancer Screening in Philadelphia Primary Care Practices • Training Primary Care Providers across Pennsylvania in SDM about Lung Cancer Screening 	<ul style="list-style-type: none"> • Liver Cancer: <ul style="list-style-type: none"> • Bio-Psycho-Social Drivers of Disparities in Liver Disease Progression among Korean Americans with Hepatitis B Infection • Cervical Cancer: <ul style="list-style-type: none"> • Hashtag HPV: Engaging Parents through Social Media to Increase HPV Vaccination • Other: <ul style="list-style-type: none"> • We Are Here: Hear Us/Estamos Aqui: Escúchenos • Telemedicine Across the Cancer Care Continuum during COVID-19 Pandemic • Community Outreach Capacity through Community Health Educator (CHE) • Multi Cancer Early Detection – Lean into the Study of Average Risk (SOAR) Trial

Division Faculty and Research Interests

Our faculty members embody a wide range of expertise, unified by a shared commitment to advancing cancer prevention and control:

- **Andrew E. Chapman, DO, FACP, Professor:** Models of care delivery in geriatric oncology.
- **Ana Maria Lopez, MD, MPH, MACP, FRCP, Professor:** Telehealth, health equity, and outreach.
- **Hee-Soon Juon, MSN, PhD, Professor:** Minority mental health, suicidal behavior, substance use, and criminal behavior. Cancer control in Asian Americans, including prevention and early detection for breast, cervical, and liver cancers, lung cancer screening, behavioral interventions, and health disparities.


- **Amy Leader, PhD, MPH, Associate Professor:** Health communication, messaging, and social media interventions. HPV vaccination/vaccine hesitancy. Community engagement, peer navigation, qualitative methods, and theory-based behavioral interventions.
- **Grace Lu-Yao, PhD, Professor:** Cancer epidemiology, geriatric oncology, and translational outcomes research related to prostate cancer and immunotherapy-treated cancers.
- **Ronald E. Myers, DSW, PhD, FSBM, Professor:** Patient adherence to cancer screening and follow-up, multi-cancer early detection, shared decision-making in screening and treatment, clinical trial participation, and implementation science.
- **Nikita Nikita, MD, MPH, Research Instructor:** Health outcomes of novel cancer therapy in older adults, geriatric oncology, prostate cancer, and host factors affecting immune checkpoint inhibitor responses.
- **Munjireen Sifat, PhD, Assistant Professor:** Culturally appropriate interventions to address health equity in cancer prevention and control (e.g., tobacco cessation, cancer screening), mHealth solutions, and community-based research.
- **Kuang-Yi Wen, PhD, Associate Professor:** Digital health promotion, improving cancer prevention and control, treatment management, lifestyle behaviors, and smoking cessation among underserved and marginalized communities.
- **Chun Wang, MD, PhD, Assistant Professor:** Identifying predictive, prognostic, and race-specific biomarkers, and constructing models for early detection and treatment outcomes in solid tumors.
- **Hushan Yang, PhD, Professor:** Genomic biomarker identification using liquid biopsies (CTCs, ctDNAs), precision medicine, and understanding molecular/genomic contributors to racial health disparities.

Multi-level Implementation Science Studies in Lung Cancer Screening:

A cornerstone of our current work is a five-year NCI-funded R01 led by Dr. Ronald E. Myers. This multi-institutional, multi-level implementation science trial (2022–2028) tests the effects of provider support and patient outreach interventions on lung cancer screening rates across 28 practices in southeastern Pennsylvania, Delaware, and New Jersey. A recently completed Pennsylvania Department of Health CURE Award subcontract and a collaborative pilot study with Drexel University have further evaluated shared decision-making interventions and the challenges of implementing lung cancer screening in primary care. These efforts have resulted in numerous conference presentations, manuscripts in progress, and a new R01 application submitted to NCI focused on increasing lung cancer screening among Black/African American communities. Additionally, we have trained genetic counseling graduate students at Jefferson in shared decision-making principles, thereby cultivating a new generation of experts in cancer prevention and control.

Expanding Research and Community Engagement:

In 2024, our grant portfolio expanded with notable achievements. Dr. Sifat published three first-author papers and co-authored 13 additional manuscripts, presenting at top-tier conferences such as SRNT, SBM, and CCCIF. Supported by a \$50,000 ACS IRG grant, our team is investigating smoking cessation interventions for formerly unhoused populations and nearing completion of another ACS project that analyzes social determinants of health in cancer patients. In partnership with Mi Salud and Dr. Brandy-Joe Milliron at Drexel, we are implementing a medical nutrition program for the Hispanic community,



funded by a Genentech Community Science Day Pilot Fund Project. Through this and other initiatives, we continue to foster meaningful relationships with community-based organizations and enhance our focus on health equity.



Congratulation to Amy Leader today was the Jefferson Ribbon Cutting - Dietz & Watson Community Outreach Unit
December 3, 2024




Advancing Biomarker Research and Precision Oncology:

The Yang lab initiatives also progressed significantly. This year, Dr. Yang, in collaboration with Dr. Chun, improved the detection sensitivity of our circulating tumor cell (CTC) enumeration pipeline. Working closely with Drs. Kelly and Zarrabi, we are exploring CTC-based precision medicine approaches for metastatic prostate cancer and, in collaboration with Dr. Joseph Curry in Head and Neck Surgery, generating preliminary data to support the use of saliva-derived CTCs as a high-performance, non-invasive biomarker for the early detection of head and neck squamous cell carcinoma (HNSCC). These findings will support future R01 submissions and accelerate the integration of precision diagnostics into routine clinical practice.

Advancing Data Science Research:

In recent years, Drs. Lu-Yao and Nikita's research portfolio has grown through the successful launch and continuation of multiple funded projects aimed at improving cancer outcomes and promoting health equity using data science approaches. Notably, our Department of Defense (DOD) study is guiding more individualized treatments to reduce disparities and enhance patient well-being for prostate cancer. Through this proposal, we collaborated with Dr. Chris Yang at Drexel and the Veterans Affairs team at Cedar Sinai. Through the SKCC Consortium Multi-PI Collaborative Grant Program, we evaluate how co-medications and co-morbidities shape immunotherapy results in lung cancer patients. Additionally, our PA Cure Grant-backed efforts focus on identifying and alleviating barriers to cutting-edge therapies among underserved populations. Collectively, these initiatives have led to six published papers,



strengthening the evidence base and advancing the adoption of targeted, culturally sensitive interventions.

Center City Hospitalist

Suchit Bhutani, MD

Section Lead, Inpatient Hospitalists


The Section of Oncology Hospitalist comprises 2 major groups, one being Solid Oncology Hospitalist and the other BMT Hospitalist. Both groups serve as a primary service for patients admitted to Center City, TJUH. There are 8 faculty members, and they have developed a niche in this subspecialty of internal medicine (hospitalist) section.

Solid Oncology Hospitalist service (known as Resident Blue 3 and Blue 4) has served as a role model for the subspecialty service line within the department, with plans to expand such primary service to other satellite locations. IM residents and SKMC students have had a robust learning experience on this service. Some of the high-yield topics that learners get exposed to are, to name a few, febrile neutropenia, chemotherapy side effects, bloodstream infections, cancer-related pain, malignant cord compression, and sometimes even end-of-life care with hospice transitions. Hospitalists work closely with oncologists in developing a care plan for the patient and make sure transitions of care are effective and safe.

BMT hospitalist is a co-managed service with the BMT Oncologist and is a well-orchestrated service line with co-management from nurses, pharmacy, coordinators, and case management. BMT line consistently has reported year after year high patient satisfaction scores.

Some of the highlights of the service line:

- Structure: One of the oldest TJUH services to maintain In-person multidisciplinary rounds to date, with participation from Oncology nurse managers, charge nurses, case managers, physical therapists, and pharmacists every weekday.
- Hospital Metrics: Oncology hospitalists have consistently met target metrics set by the Hospital Medicine Council, like utilization of discharge milestones, use of event reporting, and documentation initiatives, to name a few
- Educational Role and Contributions:
 - o Dr. Suchit Bhutani and Dr. Evan Nardone serve as core faculty for the Internal Medicine Residency Program at TJUH.
 - o Dr. Suchit Bhutani and Dr. Evan Nardone serve as leaders for CSSG (Clinical Skills Small Group) for SKMC medical students
 - o Dr. Evan Nardone serves as Director of Health System Science Curriculum for IM residency
 - o Dr. Evan Nardone will serve as a faculty lead for the 4th Health Equity and QI summit, May 2025, hosted by the Department of Medicine



- Awards: Dr. Evan Nardone received numerous teaching awards from house staff last year, including teaching attending of the year and Leonard Tow Humanism in Medicine Award through Gold Humanism Honor Society.

Medical Oncology Advanced Care Hubs

Jefferson Northeast

Marcia S. Brose, PhD, MD, FASCO

Vice Chair, Department of Medical Oncology, Jefferson Northeast

Regional Chief of Cancer Services, Sidney Kimmel Comprehensive Cancer Center

Health System Leader for Community Cancer Research, Sidney Kimmel Comprehensive Cancer Center

Chair of Hematology/Oncology, Jefferson Torresdale Hospital

As we complete our 4th year, SKCCC at Jefferson Northeast (JNE) has continued to grow to serve the communities at three hospitals, Jefferson Frankford Hospital to our south, Jefferson Torresdale Hospital to the north, and Jefferson Bucks Hospital in Bucks County. These three hospitals and the cancer patients we serve cover a large region and provide vital oncology and hematology care to a growing patient population. This year, we added four additional faculty members to meet the growing patient volumes. Our staff now boasts 11 physicians and 6 Advanced Practice Clinicians (APCs) who provide an average of 1200 infusion visits per month. With one of our new doctors, we have increased our inpatient palliative care service to include two MDs and one APC. New this year, we opened an outpatient service in Bucks County to support our patients farther north, and we hope to move that practice to our new practice location in 2025.

We have also seen growth in our support staff for our practice, which includes a part-time nutritionist, lay navigator, nurse navigators, and clinical nurses. Patients with additional needs can also be supported by our financial counselor and two full-time social workers. In the hospital, we have also added to our palliative care team, which is shared in the hospital with other departments, that can provide additional end-of-life care. Advanced capabilities at the SKCCC include Cyberknife, interventional radiology, and interventional pulmonology, which all work very closely with our team. We have continued to have close relationships with related specialties, including urology and Head and neck Surgery in addition to other internal medicine subspecialties (e.g., pulmonary, GI). Our Medical, radiation, and surgical oncologists provide inpatient consults and treatment services to patients at Jefferson Frankford, Jefferson Bucks, and Jefferson Torresdale hospitals, with integration with the outpatient program, allowing for ease of follow-up for our patients.

Jefferson Northeast also has a fully staffed clinical trial program with 4 full-time staff members now on site. Over the past year, we enrolled 5 patients in clinical trials at Jefferson Torresdale Hospital and enabled the successful referral of 5 additional patients to trials in Center City. For the first time this year, we had physicians attending all 12 enterprise-wide SKCCC multidisciplinary group meetings. This increased engagement has led to 12 newly opened clinical trials, with five additional trials in the pipeline, which will allow more patients to participate in clinical trials in our community.





Biannual Community Screening Event at Jefferson Northeast

Our site is also very involved with education. We currently supervise medical students (several a month) from local programs such as the Philadelphia College of Osteopathic Medicine and the Lake Erie College of Osteopathic Medicine, and medical students from farther away who choose our site for elective time. We continue to teach required rotations for 120 Emergency Department, Internal Medicine, and Family Medicine residents at Jefferson Northeast Hospitals, who learn about cancer in the outpatient setting.

The last major pillar of our program is community engagement. In February, we cut the ribbon for our newly established food pantry, which provides food for our patients with food insecurity. We hosted our two most successful community screening events, which now exceed 200 cancer screenings offered in one day, and added two additional screening events, one specifically for lung cancer, and one that supported two of the unions (Firefighters and steamfitters unions) in our community after hours when the members were off work. The great response to these events demonstrates a continued need in our community, which we continue to strive to meet. We added to our yearly survivorship event a second one geared specifically for our patients with breast cancer, and additionally, we continue to sponsor and host multiple additional education and awareness activities throughout the community. We partner with local high schools and student organizations to spread cancer awareness, screening, and prevention.


Spotlight: Be Kind Always & Generous When Possible

SKCCC Torresdale Food Pantry

Ribbon Cutting Ceremony – March 25, 2024

Shout-outs to

Dr. Marcia S. Brose and Teresa Giamboy





Construction is now almost complete for two new practice areas for our practice. We will be expanding our Torresdale clinical space to include 6 new exam rooms, which will allow us to offer additional services in the coming year, and a brand-new infusion suite and exam rooms at our Jefferson Bucks Hospital location, allowing us to better serve our patients in Bucks County in 2025.

Jefferson New Jersey

Anthony P. Scarpaci, MD

Vice Chair, Department of Medical Oncology, Jefferson, New Jersey

Jefferson, New Jersey: A Year of Growth, Innovation, and Compassionate Care -

This year has been a truly transformative one for the Jefferson New Jersey team, marked by exciting achievements, dynamic growth, and an unwavering commitment to excellence in patient care. A major milestone was reached in May with the grand opening of our brand-new Cancer Center, located on the 5th floor of the Jefferson Cherry Hill Medical Office Building. This beautifully designed, state-of-the-art space features 10 modern exam rooms and 20 spacious infusion bays, creating a warm and healing environment where patients receive the highest quality care. Beyond clinical treatment, patients benefit from integrated social work and navigation services, ensuring a truly holistic and supportive experience throughout their journey.






Ribbon cutting ceremony for the new Cherry Hill practice location attended by state and local officials as well as Jefferson leadership

Our practice has experienced significant and exciting growth. We proudly welcomed three highly skilled nurse practitioners and two exceptional physicians to our multidisciplinary team. Their expertise and dedication have already enhanced the strength and depth of the care we provide. In addition to team expansion, we have introduced innovative and impactful programs designed to meet the evolving needs of our patients. These include a new high-risk breast cancer clinic dedicated to individuals with genetic predispositions or complex benign conditions. We're also collaborating with our esteemed colleagues in the heart failure group to lay the foundation for a cutting-edge Cardio-Oncology program—an initiative that will bridge cardiology and oncology care for better patient outcomes. Furthermore, efforts are underway to launch a nurse practitioner-led rapid anemia clinic and to bolster our participation in the enterprise-wide Same Day/Next Day program, both of which are focused on improving patient access and care efficiency.



Outside of the clinic, our team continues to demonstrate a deep commitment to community engagement and advocacy. This year, we proudly participated in a variety of outreach initiatives, including the American Cancer Society's **Men Wear Pink** campaign, the **2024 Making Strides Against Breast Cancer, Greater Philadelphia & Southern NJ**, and a heartfelt **Survivorship Day** celebration—events that reflect the spirit of unity, hope, and support that defines our mission.

As we look back on the past year, we are filled with pride and gratitude. These accomplishments are a testament to the passion, collaboration, and resilience of our incredible team. With continued innovation and a patient-centered approach, we look forward to building an even brighter future together.



Opening of brand-new clinic and infusion space at the Cherry Hill campus in New Jersey

Jefferson Abington Hospital and Asplundh Cancer Center

Steven J. Cohen, MD

Vice Chair, Department of Medical Oncology, Jefferson Abington and Asplundh Cancer Pavilion

Chief, Division of Hematology and Oncology, Jefferson Abington Hospital

Chief of Cancer Services, Jefferson Abington Hospital and Asplundh Cancer Pavilion

Enterprise Chief of GI Medical Oncology

The Asplundh Medical Oncology group is currently composed of 12 hematologists/medical oncologists and 7 Advanced Practice Clinicians (APCs). The group is led by Dr. Steven Cohen, who serves as Chief of the Division of Hematology/Oncology at Jefferson Abington Hospital, Chief of Cancer Services at Jefferson Abington Hospital, and Asplundh Cancer Pavilion. He is also a vice-chair in the department of medical oncology at TJUH and oversees GI Medical Oncology for Jefferson Health. Dr. Christian (CJ) Fidler serves as the clinical director of operations (DCO). Dr. Sheel Patel oversees clinical trial research for hematology/oncology. Dr. Avnish Bhatia oversees the same-day/next-day program. All of the faculty members have a disease site of focus (breast, lung, GI, malignant hematology, GU, head and neck, melanoma) and actively participate in disease-specific MDGs and tumor boards.

Of our 7 Advanced Practice Clinicians (APCs), one is exclusively GI-focused (with Dr. Cohen), 5 are aligned with care teams with 2-3 physicians, and 1 is exclusively inpatient. Our physicians rotate in covering a busy inpatient consult service (averaging 30+ patients at a time) and spend an average of 6

weeks inpatient. The group's outpatient practice is at Asplundh Cancer Pavilion, which is a TJUH and SKCC facility, but the inpatient consult work is at Jefferson Abington Hospital. The clinical practice is busy, seeing over 100 patients/day outpatient and treating over 90 patients/day in the infusion unit at Asplundh.



Our physicians participate in Multidisciplinary Disease Group (MDG) meetings according to their disease area of focus. We open appropriate clinical trials at Asplundh for our patient population in collaboration with our Center City colleagues and participate in enterprise-wide tumor boards and clinical/research meetings. Dr. Melanie Nordlinger was a co-author on a Journal of Clinical Oncology study in head and neck cancer (Dzienis et al. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial. J Clin Oncol. 20.

In terms of education, we have an Abington-specific fellowship position, which is a separate track of the Jn hematology and oncology fellowship, and we have 3 fellows now (one for each year) who each spend 4 months rotating in the OP realm at Asplundh and the inpatient consult service at Jefferson Abington Hospital. We have several Jefferson/Abington internal medicine residents who rotate with us on a regular basis to gain additional experience in hematology/oncology. We also have a fair number of external internal medicine residents. We provide lectures for the Jefferson Abington internal medicine residency as a whole in hematology/oncology.

Our general longer-term goal is to more closely align each physician with disease teams at TJUH/SKCC and provide time for academic endeavors. Our physicians are employed through Jefferson Medical Group. As such, they are expected to provide 9 sessions/week of outpatient care in addition to regular rotations on the inpatient service. Time is the biggest limitation for more academic engagement of our Asplundh/Abington providers, and working with the institution to provide some additional protected time for academic endeavors.

Jefferson Einstein Philadelphia

John C. Leighton Jr, MD

Vice Chair, Department of Medical Oncology, Jefferson Einstein

Associate Medical Director-Oncology, Moha –Einstein

The Jefferson Einstein Philadelphia Medical Oncology and Hematology Division and the Section of Radiation Oncology serve the clinical needs of a community that extends from Northeast Philadelphia with a Cancer Facility at the Jefferson Einstein Center One location to North Philadelphia with a Cancer Center at the Jefferson Einstein Philadelphia campus. The largest site of activity is at the Jefferson Einstein Philadelphia campus in North Philadelphia, where we serve one of the most diverse and disadvantaged populations in the United States. Einstein is considered a private healthcare safety-net hospital, bearing a large share of responsibility for caring for the poor as measured by services to Medicaid, Medicare, SSI, and uninsured patients. More than 87% of the patients at Einstein are covered

by Medicare, Medicaid or are uninsured. We have a dual reporting structure as we are under the Sidney Kimmel Cancer Center and the Department of Medical Oncology at Jefferson and are part of the Department of Medicine at Einstein.



The Medical Oncology and Hematology Faculty are responsible for clinical care in a multidisciplinary environment and academic commitment to our Hematology Fellowship Program and the Internal Medicine Residency Program at Einstein. The faculty has won multiple internal teaching awards over the years. The Fellowship Program graduated two fellows for the first time in 2024. The faculty serve as mentors to the residents, and in December 2024, four of the Jefferson Einstein Philadelphia Internal Medicine Residents matched for

Hematology Oncology Fellowship Programs throughout the country and will start training in July 2025, while we filled the two positions in our program. The Fellows and Residents mentored by the faculty have presented their work at multiple meetings, including ASCO and ASH in the current year. Also in the current year, Zachary Cohn, MD, was nominated by the House Staff for a Faculty Teaching Award, and Claudia Dourado was the Jefferson Einstein Philadelphia Faculty Member of the Month in February 2024.

There are 6 board-certified or board-eligible hematologists and oncologists responsible for the clinical, academic, and research mission of the Philadelphia campus. Three physicians, Drs. Leighton, Dourado, and Varadi have academic appointments through the Sidney Kimmel Medical College. We are one of the busiest Hematology-Oncology programs from a clinical perspective and treat patients with many medical and psychosocial comorbidities. Common cancers that we treat are colon, breast, lung, liver, prostate, and multiple myeloma. We see approximately 60% of classical hematology patients, ranging from iron deficiency anemia to complicated cases of hemophagocytic syndrome and TTP that are managed internally. We have over 10 multidisciplinary tumor boards across the campuses that are very collegial and educational activities designed to offer our patients optimal multidisciplinary care. The group has also been more active in the SKCC Multidisciplinary Groups. Jefferson Einstein Philadelphia has grown a Cardio-Oncology Program in the past year and developed a Psycho-Oncology Program in collaboration with the Department of Psychiatry. A collaboration with the Geriatric Division to perform geriatric assessment on all appropriate patients is intended to launch in early 2025.

Our group has demonstrated a greater commitment to clinical research in 2024 through the support of SKCC. We remain involved in research projects with our fellows and students. We reopened our research program with the support of the clinical trials office of the Sidney Kimmel Cancer Center and our Department of Urology. We have enrolled 20 patients on clinical trials in 2024 to date, with our highest accruing trials including a partnership with the Population Science Division on electronic patient-reported outcome assessments in patients with multiple myeloma and an investigator-initiated trial through Merck evaluating educational models for adherence to oral antineoplastic medications.

We have recruited a faculty member with a keen interest in multiple myeloma and are hoping in 2025 to open trials for patients with multiple myeloma at our site as this is one of our 6 most common malignancies.

Because our access to Jefferson medical students is limited, we do not have as many faculty appointments as we would like. We are looking for opportunities to allow each Einstein faculty member to become a faculty member of the Medical College. In the upcoming years, we are committed to providing the highest quality care to the population we serve and are hopeful of growing our practice within North Philadelphia, bringing more clinical trials to our population with greater identification of tumor specific biomarkers for each patient and providing access to state-of-the-art therapies beginning with bispecific antibodies and ultimately cellular therapies.

Jefferson Einstein Montgomery

Marcia S. Brose, PhD, MD, FASCO

*Vice Chair, Department of Medical Oncology, Jefferson Northeast, Jefferson Einstein Montgomery
Regional Chief of Cancer Services, Sidney Kimmel Comprehensive Cancer Center*

*Health System Leader for Community Cancer Research, Sidney Kimmel Comprehensive Cancer Center
Chair of Hematology/Oncology, Jefferson Einstein Montgomery Hospital*



SKCCC at Jefferson Einstein Montgomery Hospital (JEM) provides an important access point for cancer care for patients from northern Montgomery County and points north and west. The SKCCC practice at JEM was revitalized in 2024 with the addition of vital staff and providers. In 2024, we took the medical staff from 2.5 to 5 faculty members, significantly increasing our capacity and access for patients. We continue to provide on-site radiation oncology services as well for our patients with the

participation of two providers and support staff in the same building and provide additional convenience for our patients who require radiation during chemotherapy. The SKCCC for JEM was reaccredited by both the COC and NAPBC this year.


During 2024, we also added 6 positions to our support staff for our practice, which includes a part-time nutritionist, lay and nurse navigators, and infusion and clinic nurses. Additionally, we provide on-site palliative care and cancer genetics counseling. Patients with additional needs are also supported by our financial counselor and our full-time social workers.

Our site is also very involved in education. Several lectures on cancer prevention were given by our staff to local community groups on topics such as lung cancer screening, and additional site-specific events for breast, lung and colorectal cancer. A survivorship symposium provided additional

education to our patients and their families. Cancer screening events for breast and skin cancer were also well attended.



At Jefferson Einstein Montgomery (JEM), we have seen a significant increase in the need for our services in the northwest suburbs and look forward to additional growth to meet those needs coming in 2025.



Appendix A

Medical Oncology Publications List (does not include non-SKCCC publications prior to 2012) (01/01/2024 - 12/31/2024)

Terai M[MONC], Sato T[MONC]. Individualised neoantigen cancer vaccine therapy. *Lancet* [98.4]. 2024 Feb 17; 403(10427):590-591.

Piulats JM, Watkins C, Costa-García M, Del Carpio L, Piperno-Neumann S, Rutkowski P, Hassel JC, Espinosa E, de la Cruz-Merino L, Ochsenreither S, Shoushtari AN, Orloff M[MONC], Salama AKS, Goodall HM, Baurain JF, Nathan P. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis. *Ann Oncol* [56.7]. 2024 Mar; 35(3):317-326.

Wirth LJ, Brose MS[MONC], Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA. Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. *J Clin Oncol* [42.1]. 2024 Aug 02:JCO2302503. [Epub ahead of print]

Bashir B[MONC], Wang JS, Falchook G, Fontana E, Arkenau HT, Carter L, Galot R, Basu B, Greystoke A, Subbiah V, Richardson DL, Orr H, Bennett G, Sharma R, Xu H, Paganoni P, Xu C, Campbell C, McKean M. Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. *J Clin Oncol* [42.1]. 2024 Sep 04:JCO2301107. [Epub ahead of print]

Kelly WK[MONC], Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, Armstrong AJ, Pook D, Kim M, Dorff TB, Fischer S, Lin YC, Horvath LG, Sumey C, Yang Z, Jurida G, Smith KM, Connarn JN, Penny HL, Stieglmaier J, Appleman LJ. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. *Cancer Discov*[30.6]. 2024 Jan 12; 14(1):76-89.

Leader AE[MONC], McNair CM[MONC], Johnson JM[MONC]. From Base Pairs to City Squares: Comprehensive Precision Oncology for the Future. *Cancer Discov*[30.6]. 2024 Apr 04; 14(4):569-572.

Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, Ibrahim ML, McGraw KL, Wysota M[MONC], Aldrich AL, Ryder CB, Letson CT, Traina J, McLemore AF, Droin N, Shastri A, Yun S, Solary E, Sallman DA, Beg AA, Ma L, Gaspar-Maia A, Patnaik MM, Padron E. RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis. *Cancer Discov*[30.6]. 2024 Aug 27. [Epub ahead of print]

Marshall CH, Teply BA, Lu J, Oliveira L, Wang H, Mao SS, Kelly WK[MONC], Paller CJ, Markowski MC, Denmeade SR, King S, Sullivan R, Davicioni E, Proudfoot JA, Eisenberger MA, Carducci MA, Lotan TL,

Antonarakis ES. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial. *JAMA Oncol* [22.5]. 2024 Aug 22. [Epub ahead of print]

von Jan J, Timonen S, Braun T, Jiang Q, Ianevski A, Peng Y, McConnell K, Sindaco P, Müller TA, Pützer S, Klepzig H, Jungherz D, Dechow A, Wahnschaffe L, Giri AK, Kankainen M, Kuusanmäki H, Neubauer HA, Moriggl RH, Mazzeo P, Schmidt N, Koch R, Hallek MJ, Chebel A, Armisen D, Genestier L, Bachy E, Mishra A[MONC], Schrader A, Aittokallio T, Mustjoki S, Herling M. Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses. *Blood* [21]. 2024 Jun 28. [Epub ahead of print]

Verrillo CE, Quaglia F, Shields CD, Lin S, Kossenkova AV, Tang HY, Speicher D, Naranjo NM, Testa A, Kelly WK[MONC], Liu Q, Leiby B, Musante L, Sossey-Alaoui K, Dogra N, Chen TY, Altieri DC, Languino LR. Expression of the $\alpha V\beta 3$ integrin affects prostate cancer sEV cargo and density and promotes sEV pro-tumorigenic activity in vivo through a GPI-anchored receptor, NgR2. *J Extracell Vesicles* [15.5]. 2024 Aug; 13(8): e12482.

Batty GD, Kivimäki M, Almquist YB, Eriksson JG, Gissler M, Gnanamanickam ES, Hamer M, Jackisch J, Juon HS[MONC], Keski-Säntti M, Li C, Mikkola TM, Murray E, Sacker A, Segal L, Frank P. Cardiovascular disease in adults with a history of out-of-home care during childhood: a systematic review and meta-analysis of prospective cohort studies. *Lancet Reg Health Eur*[13.6]. 2024 Aug; 43:100984.

Banner L, Rohan TZ, Zachian R, Gross T, Yang HY, Joffe D, Porcu P[MONC], Nikbakht N. Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A Surveillance, Epidemiology, and End Results database analysis. *J Am Acad Dermatol* [12.8]. 2024 Jul; 91(1):151-153.

Burus T, VanHelene AD, Rooney MK, Lang Kuhs KA, Christian WJ, McNair C[MONC], Mishra S, Paulino AC, Smith GL, Frank SJ, Warner JL. Travel-Time Disparities in Access to Proton Beam Therapy for Cancer Treatment. *JAMA Netw Open* [10.5]. 2024 May 01; 7(5): e2410670.

Kendzor DE, Businelle MS, Frank-Pearce SG, Waring JJC, Chen S, Hébert ET, Swartz MD, Alexander AC, Sifat MS[MONC], Boozary LK, Wetter DW. Financial Incentives for Smoking Cessation Among Socioeconomically Disadvantaged Adults: A Randomized Clinical Trial. *JAMA Netw Open* [10.5]. 2024 Jul 01; 7(7): e2418821.

Rising KL, Guth A, Gentsch AT, Martin Gonzalez K, Hass R, Shughart L, Gelfer S, McVane M, Worster B, Leader AE[MONC]. Development and Preliminary Validation of a Screener for Digital Health Readiness. *JAMA Netw Open* [10.5]. 2024 Sep 03; 7(9): e2432718.

Makker V, Taylor MH, Aghajanian C, Cohn AL, Brose MS[MONC], Simone CD, Cao ZA, Suttner L, Loboda A, Cristescu R, Jelinic P, Orlowski R, Dutta L, Matsui J, Dutcus CE, Minoshima Y, Messing MJ. Evaluation

of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. *J Immunother Cancer* [10.3]. 2024 Jan 19; 12(1).

Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rieth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, Sato T[MONC]. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. *J Immunother Cancer* [10.3]. 2024 Jun 06; 12(6).

Zimmerman MKA, Wilde L[MONC]. Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon. *Am J Hematol*[10.1]. 2024 Aug 28. [Epub ahead of print]

Patel SP, Othus M, Chae YK, Dennis MJ, Gordon S[MONC], Mutch D, Samlowski W, Robinson WRR, Sharon E, Ryan C, Lopez G, Plets M, Blanke C, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. *Clin Cancer Res* [10]. 2024 Jan 05; 30(1):33-38.

Hanna GJ, Grover P, Elliott A, McGrath J, Xiu J, Sukari A, Johnson JM[MONC], Wise-Draper T. Molecular Profiling, and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II. *Clin Cancer Res* [10]. 2024 May 15; 30(10):2225-2232.


Wen KY[MONC], Burke SE, Jacoby JL, Liang J, Simone NL. RE: Dietary interventions in cancer: a systematic review of all randomized controlled trials. *J Natl Cancer Inst* [9.9]. 2024 Aug 01; 116(8):1402-1403.

Burus T, McAfee CR, Hull PC, Leader AE[MONC], McNair C[MONC]. Tracking Community Outreach and Engagement Activities among National Cancer Institute-Designated Cancer Centers. *J Natl Cancer Inst* [9.9]. 2024 Sep 23. [Epub ahead of print]

El Khoury CJ, Freedland SJ, Gandhi K, Keith SW, Nikita N[MONC], Shaver A[MONC], Sharma S, Kelly WK[MONC], Lu-Yao G[MONC]. Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study. *J Natl Cancer Inst* [9.9]. 2024 Sep 23. [Epub ahead of print]

Li D, Loriot Y, Burgoyne AM, Cleary JM, Santoro A, Lin D[MONC], Aix SP, Garrido-Laguna I, Sudhagani R, Guo X, Andrianova S, Paulson S. Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021). *EClinicalMedicine*[9.6]. 2024 Jan; 67:102376.

Argiris A, Flamand Y, Savvides P, Johnson JM[MONC], Vathiotis I, Levine M, Li S, Forastiere AA, Burtneess B. A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305. *Eur J Cancer* [7.6]. 2024 Mar; 199:113509.



Haverkos B, Zain J, Kamdar M, Neuwelt A, Davila E, Bradeen X, Major A, Bair S, Jasem J, Smith C, Abbott D, Porcu P[MONC]. Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial. *Blood Adv* [7.4]. 2024 Feb 13; 8(3):708-711.

Maziarz RT, Gergis U[MONC], Edwards ML, Song Y, Liu Q, Anderson A, Signorovitch J, Manghani R, Simantov R, Shin H, Sivaraman S. Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective. *Blood Adv* [7.4]. 2024 Mar 12; 8(5):1200-1208.

Bhansali RS, Ellin F, Relander T, . . . Porcu P[MONC], . . . Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. *Blood Adv* [7.4]. 2024 Jul 09; 8(13):3507-3518.

Grosso D, Wagner JL, O'Connor A, Keck K, Huang Y, Wang ZX, Mehler H, Leiby B, Flomenberg P, Gergis U[MONC], Nikbakht N, Morris M, Karp J, Peedin A, Flomenberg N. Safety, and feasibility of third-party cytotoxic T lymphocytes for high-risk patients with COVID-19. *Blood Adv* [7.4]. 2024 Aug 13; 8(15):4113-4124.


Jain T, Estrada-Merly N, Salas MQ, . . . Gergis U[MONC], . . . Scott BL, Saber W, Gupta V. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study. *Blood Adv* [7.4]. 2024 Aug 27; 8(16):4281-4293.

Maruyama D, Jacobsen E, Porcu P[MONC], Allen P, Ishitsuka K, Kusumoto S, Narita T, Tobinai K, Foss F, Tsukasaki K, Feldman T, Imaizumi Y, Izutsu K, Morishima S, Yamauchi N, Yuda J, Brammer JE, Kawamata T, Ruan J, Nosaka K, Utsunomiya A, Wang J, Zain J, Kakurai Y, Yamauchi H, Hizukuri Y, Biserna N, Tachibana M, Inoue A, Horwitz SM. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. *Lancet Oncol* [41.6]. 2024 Oct 29. [Epub ahead of print]

Sardar S, McNair CM[MONC], Ravindranath L, Chand SN, Yuan W, Bogdan D, Welti J, Sharp A, Ryan NK, Knudsen LA, Schiewer MJ, DeArment EG, Janas T, Su XA, Butler LM, de Bono JS, Frese K, Brooks N, Pegg N, Knudsen KE, Shafi AA. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. *Oncogene* [6.9]. 2024 Sep 13. [Epub ahead of print]

Chua V, Lopez-Anton M, Mizue Terai, Ryota Tanaka, Baqai U, Purwin TJ, Haj JI, Waltrich FJ, Trachtenberg I, Luo K, Tudi R, Jeon A, Han A, Chervoneva I, Davies MA, Aguirre-Ghiso JA, Sato T[MONC], Aplin AE. Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. *Sci Signal* [6.7]. 2024 Jun 11; 17(840): eadn8376.

Worster B, Meghani SH, Leader AE[MONC], Nugent SM, Jones KF, Yeager KA, Liou K, Ashare RL. Toward reducing racialized pain care disparities: Approaching cannabis research and access through the lens of equity and inclusion. *Cancer* [6.1]. 2024 Feb 15; 130(4):497-504.



Philips R, Alnemri A, Amin D, Patel J, Topf MC, Johnson JM[MONC], Bar-Ad V, Axelrod R[MONC], Argiris A, Fundakowski C, Luginbuhl AJ, Cognetti DM, Curry JM. Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer. *Cancer* [6.1]. 2024 Mar 15; 130(6):863-875.

Ji J, Bae M, Sun CL, Wildes TM, Freedman RA, Magnuson A, O'Connor T, Moy B, Klepin HD, Chapman AE[MONC], Tew WP, Dotan E, Fenton MA, Kim H, Katheria V, Gross CP, Cohen HJ, Muss HB, Sedrak MS. Falls prechemotherapy and toxicity-related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial. *Cancer* [6.1]. 2024 Mar 15; 130(6):936-946.

Volk RJ, Myers RE[MONC], Arenberg D, Caverly TJ, Hoffman RM, Katki HA, Mazzone PJ, Moulton BW, Reuland DS, Tanner NT, Smith RA, Wiener RS. The American Cancer Society National Lung Cancer Roundtable strategic plan: Current challenges and future directions for shared decision making for lung cancer screening. *Cancer* [6.1]. 2024 Sep 20. [Epub ahead of print]


Armache M, Assi S, Wu R, Jain A, Lu J, Gordon L, Jacobs LM, Fundakowski CE, Rising KL, Leader AE[MONC], Fakhry C, Mady LJ. Readability of Patient Education Materials in Head and Neck Cancer: A Systematic Review. *JAMA Otolaryngol Head Neck Surg*[6]. 2024 Aug 01; 150(8):713-724.

Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS[MONC]. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. *Thyroid*[5.8]. 2024 Jan; 34(1):26-40.

Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytsky R, Oliver J, Keam B, Brose MS[MONC]. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. *Thyroid*[5.8]. 2024 Mar; 34(3):347-359.

Hassel JC, Stanhope S, Greenshields-Watson A, Machiraju D, Enk A, Holland C, Abdullah SE, Benlahrech A, Orloff M[MONC], Nathan P, Piperno-Neumann S, Staeger R, Dummer R, Meier-Schiesser B. Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. *J Invest Dermatol*[5.7]. 2024 Jul 15. [Epub ahead of print]

Vandekerkhove G, Giri VN, Halabi S, McNair C[MONC], Hamade K, Bitting RL, Wyatt AW. Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. *JCO Precis Oncol*[5.3]. 2024 Mar; 8:e2300654.



Loeb S, Keith SW, Cheng HH, Leader AE[MONC], Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown LH, Pieczonka CM, Gomella LG, Kelly WK[MONC], Lallas CD, Handley N[MONC], Mille PJ[MONC], Mark JR, Brown GA, Chopra S, McClellan A, Wise DR, Hollifield L, Giri VN. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. *JCO Precis Oncol*[5.3]. 2024 Mar; 8:e2300552.

Loeb S, Cheng HH, Paller CJ, Weg E, Johnson J[MONC], Gross L, Keith SW, Russo J, Hathaway F, Rivera A, Giri VN. Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board. *Prostate Cancer Prostatic Dis*[5.1]. 2024 Jan 03. [Epub ahead of print]

Nixon AB, Liu Y, Yang Q, Luo B, Starr MD, Brady JC, Kelly WK[MONC], Beltran H, Morris MJ, George DJ, Armstrong AJ, Halabi S. Prognostic, and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab. *Prostate Cancer Prostatic Dis*[5.1]. 2024 Feb 12. [Epub ahead of print]

Zhang Z, Luo R, Kelly WK[MONC], Chen J, Donahue S, Ip K, Handley NR[MONC], Tester WJ[MONC], Tsang ML, Kim FJ, Myers R[MONC], Lu-Yao G[MONC], Gu J, Lin J, Li B, Wang C, Yang H[MONC]. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer. *Prostate Cancer Prostatic Dis*[5.1]. 2024 Jun; 27(2):339-347.


Al-Juhaishi T, Dela Cruz S, Gupta R, Keiffer G[MONC], Morrison VA, Shapira I, Woods A, Norsworthy K, de Claro RA, Theoret MR, Garg R, Pulte ED. Treatment of Acute Myeloid Leukemia in the Community Setting. *Oncologist*[4.8]. 2024 Aug 19. [Epub ahead of print]

Lacey J, Huston A, Lopez G, Vozmediano JR, Lam CS, Narayanan S, Lu W, Wolf U, Subbiah IM, Richard P, Lopez AM[MONC], Rao S, Frenkel M. Establishing an Integrative Oncology Service: Essential Aspects of Program Development. *Curr Oncol Rep*[4.7]. 2024 Mar; 26(3):200-211.

Tucker-Seeley R, Abu-Khalaf M[MONC], Bona K, Shastri S, Johnson W, Phillips J, Masood A, Moushey A, Hinyard L. Social Determinants of Health, and Cancer Care: An ASCO Policy Statement. *JCO Oncol Pract*[4.7]. 2024 May; 20(5):621-630.

Kasner M[MONC], Fritsche AH, Leong MC, Cameron K, Lee CB, Lin TL, Lee JH, Brogan F, Kovak MR, Honeycutt H, Shaw K, George TJ. North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era. *JCO Oncol Pract*[4.7]. 2024 Jul 01:OP2400164. [Epub ahead of print]

Klassen AC, Lee G, Chiang S, Murray R, Guan M, Lo WJ, Hill L, Leader AE[MONC], Manganello J, Massey PM. Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey. *Vaccine*[4.5]. 2024 Mar 07; 42(7):1704-1713.



Bekteshi V, Sifat M[MONC], Kendzor DE. Reaching the unheard: overcoming challenges in health research with hard-to-reach populations. *Int J Equity Health*[4.5]. 2024 Mar 18; 23(1):61.

Adams CM, McBride A, Michener P, Shkundina I, Mitra R, An HH, Porcu P[MONC], Eischen CM. Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma. *Cancers (Basel)*[4.5]. 2024 Jun 03; 16(11).

Bekadja MA, Niederwiser D, Kharfan-Dabaja MA, El Fakih R, Garderet L, Yakoub-Agha I, Greinix H, Weisdorf DJ, Galeano S, Ahmed SO, Chabanon C, Hashmi SK, Ruggeri A, Gergis U[MONC], Bazarbachi A, Hamad N, Albeihany A, Pasquini M, Hanbali A, Szer J, Kodera Y, Kumar A, Elhassan T, McLornan D, Worel N, Greco R, Mohty M, Atsuta Y, Koh M, Sureda A, Rondelli D, Aljurf M, Rasheed W. Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation. *Bone Marrow Transplant*[4.5]. 2024 Oct 07. [Epub ahead of print]

Lefler DS, Manobianco SA, Bashir B[MONC]. Immunotherapy resistance in solid tumors: mechanisms and potential solutions. *Cancer Biol Ther*[4.4]. 2024 Dec 31; 25(1):2315655.

Naranjo NM, Kennedy A, Testa A, Verrillo CE, Altieri AD, Kean R, Hooper DC, Yu J, Zhao J, Abinader O, Pickles MW, Hawkins A, Kelly WK[MONC], Mitra R, Languino LR. Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma. *Cancer Biol Ther*[4.4]. 2024 Dec 31; 25(1):2364433.


Palecki J, Bhasin A, Bernstein A, Mille PJ[MONC], Tester WJ[MONC], Kelly WK[MONC], Zarrabi KK[MONC]. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer. *Cancer Biol Ther*[4.4]. 2024 Dec 31; 25(1):2356820.

Eturi A, Bhasin A, Zarrabi KK[MONC], Tester WJ[MONC]. Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma. *Molecules*[4.2]. 2024 Apr 22; 29(8).

Lin Z, Roche ME, Díaz-Barros V, Domingo-Vidal M, Whitaker-Menezes D, Tuluc M, Uppal G, Caro J, Curry JM, Martinez-Outschoorn U[MONC]. MiR-200c reprograms fibroblasts to recapitulate the phenotype of CAFs in breast cancer progression. *Cell Stress*[4.1]. 2024; 8:1-20.

Rosenbaum SR, Caksa S, Stefanski CD, Trachtenberg IV, Wilson HP, Wilski NA, Ott CA, Purwin TJ, Haj JI, Pomante D, Kotas D, Chervoneva I, Capparelli C[MONC], Aplin AE. SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death. *Mol Cancer Res*[4.1]. 2024 Feb 01; 22(2):209-220.

Brose MS[MONC], Capdevila J, Elisei R, Bastholt L, Führer-Sakel D, Leboulleux S, Sugitani I, Taylor MH, Wang Z, Wirth LJ, Worden FP, Bernard J, Caferra P, Colzani RM, Liu S, Schlumberger M. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. *Endocr Relat Cancer*[4.1]. 2024 Aug 01; 31(8).



Seedor RS[MONC], Aplin AE, Bertolotto C, Carvajal RD, Deacon N, Doble K, Hamid O, Haq R, Kadosh M, Khan S, Kraska J, Lutzky J, McKean M, Montazeri K, Moser J, Onken M, Orloff M[MONC], Sacco JJ, Smalley K, Selig SM. Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023. *Pigment Cell Melanoma Res*[3.9]. 2024 Oct 09. [Epub ahead of print]

Chakravarti N[MONC], Boles A, Burzinski R, Sindaco P, Isabelle C, McConnell K, Mishra A[MONC], Porcu P[MONC]. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways. *Sci Rep*[3.8]. 2024 Apr 23; 14(1):9305.

Ozaki M, Kageyama K, Kimura K, Eguchi S, Yamamoto A, Tanaka R, Nota T, Yonezawa H, Nishiofuku H, Sakai Y, Tani N, Jogo A, Terai M[MONC], Sato T[MONC], Ishizawa T, Miki Y. A rat-based preclinical platform facilitating transcatheter hepatic arterial infusion in immunodeficient rats with liver xenografts of patient-derived pancreatic ductal adenocarcinoma. *Sci Rep*[3.8]. 2024 May 08; 14(1):10529.


Wen KY[MONC], Dayaratna S, Slamon R, Granda-Cameron C, Tagai EK, Kohler RE, Hudson SV, Miller SM. Chatbot-interfaced and cognitive-affective barrier-driven messages to improve colposcopy adherence after abnormal Pap test results in underserved urban women: A feasibility pilot study. *Transl Behav Med*[3.6]. 2024 Jan 11; 14(1):1-12.

Williams LS, Williams KM, Gillis N, Bolton K, Damm F, Deutch NT, Farhadfar N, Gergis U[MONC], Keel SB, Michelis FV, Panch SR, Porter CC, Sucheston-Campbell L, Tamari R, Stefanski HE, Godley LA, Lai C. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation. *Transplant Cell Ther*[3.6]. 2024 Mar; 30(3):255-267.

Collins ML, Mack SJ, Whitehorn GL, Till BM, Grenda TR, Evans NR, Gordon SW[MONC], Okusanya OT. Access to Guideline Concordant Care for Node-Positive Non-Small Cell Lung Cancer in the United States. *Ann Thorac Surg*[3.6]. 2024 Mar; 117(3):568-575.

Ahmed N, Sun F, Teigland C, Kilgore KM, Mohammadi I, Chambers J, Dieyi C, Feng C, Osborn J, Fu C, Gergis U[MONC]. Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers. *Transplant Cell Ther*[3.6]. 2024 Jul; 30(7):714-725.

Ballen K, Wang T, He N, Knight JM, Hong S, Frangoul H, Verdonck LF, Steinberg A, Diaz MA, LeMaistre CF, Badawy SM, Pu JJ, Hashem H, Savani B, Sharma A, Lazarus HM, Abid MB, Tay J, Rangarajan HG, Kindwall-Keller T, Freytes CO, Beitinjane A, Winestone LE, Gergis U[MONC], Farhadfar N, Bhatt NS, Schears RM, Gómez-Almaguer D, Aljurf M, Agrawal V, Kuwatsuka Y, Seo S, Marks DI, Lehmann L, Wood WA, Hashmi S, Saber W. Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation. *Transplant Cell Ther*[3.6]. 2024 Jul 20. [Epub ahead of print]



Bi X[MONC], Grosso D, Gradone A, Filicko-O'Hara J[MONC], McCorkell KA, O'Hara W, Wagner JL, Flomenberg N, Gergis U[MONC]. A Tender Reduced-Intensity Conditioning for the Unfit: A Novel 4 Gy Total Body Irradiation-Based Conditioning Followed by Two-Step Haploidentical Stem Cell Transplant, Results of a Prospective Trial. *Transplant Cell Ther*[3.6]. 2024 Jul 30. [Epub ahead of print]

Estephan LE, Kumar G, Stewart M, Banoub R, Linnenbach A, Harshyne LA, Martinez-Outschoorn UE[MONC], Mahoney MG, Curry JM, Johnson J, South AP, Luginbuhl AJ. Altered extracellular matrix correlates with an immunosuppressive tumor microenvironment and disease progression in younger adults with oral cavity squamous cell carcinoma. *Front Oncol*[3.5]. 2024; 14:1412212.

Gianoukakis AG, Choe JH, Bowles DW, Brose MS[MONC], Wirth LJ, Owonikoko T, Babajanyan S, Worden FP. Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer. *Eur Thyroid J*[3.5]. 2024 Feb 01; 13(1).


Heimovaara JH, van Calsteren K, Lok CAR, Evens AM, Hoegl J, Ferber A[MONC], Fernandes A, Vriens I, van Zuylen L, Amant F. Results of an international survey on the current organization of care for pregnant women with cancer. *Acta Obstet Gynecol Scand*[3.5]. 2024 Apr; 103(4):751-756.

Leader AE[MONC], Rebbeck TR, Oh WK, Patel AV, Winer EP, Bailey LO, Gomella LG, Lumpkins CY, Garraway IP, Aiello LB, Baskin ML, Cheng HH, Cooney KA, Ganzak A, George DJ, Halabi S, Hathaway F, Healy C, Kim JW, Leapman MS, Loeb S, Maxwell KN, McNair C[MONC], Morgan TM, Prindeville B, Soule HR, Steward WL, Suttiratana SC, Taplin ME, Yamoah K, Fortune T, Bennett K, Blanding-Godbolt J, Gross L, Giri VN. Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing. *BMC Public Health*[3.5]. 2024 Sep 18; 24(1):2533.

Khera N, Edwards ML, Song Y, Sun R, Manghani R, Shin H, Simantov R, Signorovitch J, Sivaraman S, Gergis U[MONC]. Projected Impact of Omidubicel-only on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies. *Adv Ther*[3.4]. 2024 Apr; 41(4):1637-1651.

Zager JS, Orloff M[MONC], Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheeler M, Ottensmeier CH. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. *Ann Surg Oncol*[3.4]. 2024 Aug; 31(8):5340-5351.

Zager JS, Orloff M[MONC], Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheeler M, Ottensmeier CH. ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study. *Ann Surg Oncol*[3.4]. 2024 Aug; 31(8):5220-5221.



Poiset SJ, Shah S, Cappelli L, Anne P, Mooney KE, Werner-Wasik M, Laufer TS, Posey JA, Lin D[MONC], Basu Mallick A, Lavu H, Bashir B[MONC], Yeo CJ, Mueller AC. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma. *Radiat Oncol*[3.3]. 2024 May 29; 19(1):65.

Kulkarni AA, Hennessy C, Wilson G, Ramesh V, Hwang C, Awosika J, Bakouny Z, Khan H, Vilar-Compte D, McKay R, Jani C, Weissmann L, Griffiths E, Batist G, Bouganim N, Mavromatis B, Bashir B[MONC], Nguyen RH, Riess JW, Puc M, Kasi A, Berg S, Castillo DR, Hayes-Lattin B, Hosmer W, Flora D, Mishra S, French B, Warner JL, Lopes G, Peters S, Florez N. Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis. *Clin Lung Cancer*[3.3]. 2024 Jul; 25(5):e229-e237.e7.

Burus T, Martinez J, DelNero P, Pepper S, Ratnayake I, Oh DL, McNair C[MONC], Krebill H, Mudaranthakam DP. Interinstitutional Approach to Advancing Geospatial Technologies for US Cancer Centers. *JCO Clin Cancer Inform*[3.3]. 2024 Aug; 8:e2400099.

Rshaidat H, Mack SJ, Koeneman SH, Martin J, Whitehorn GL, Madeka I, Gordon SW[MONC], Okusanya OT. The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients With Lung Cancer. *Clin Lung Cancer*[3.3]. 2024 Sep 24. [Epub ahead of print]


Hoadley A, Fleisher L, Kenny C, Kelly PJ, Ma X, Wu J, Guerra C, Leader AE[MONC], Alhajji M, D'Avanzo P, Landau Z, Bass SB. Exploring Racial Disparities in Awareness and Perceptions of Oncology Clinical Trials: Cross-Sectional Analysis of Baseline Data From the mychoice Study. *JMIR Cancer*[3.3]. 2024 Sep 30; 10:e56048.

Nolan M, Waring JJC, Noble B, Bradley D, Olurotimi O, Fronheiser J, Sifat M[MONC], Boozary LK, McQuoid J, Kendzor DE, Alexander AC. The Association of Cultural Identification with Obesity among African Americans. *J Racial Ethn Health Disparities*[3.2]. 2024 Jun; 11(3):1385-1393.

Ben-Arye E, Lopez AM[MONC], Daoud N, Zoller L, Walker E, Davidescu M, Shulman K, Gressel O, Stein N, Brosh S, Schiff E, Samuels N. Identifying Factors Associated With Disparities in Access to Integrative Oncology Program. *J Pain Symptom Manage*[3.2]. 2024 Jul; 68(1):10-21.

Granda-Cameron C, Kates J, Wen KY[MONC]. mHealth Interventions to Improve the Breast Cancer Continuum of Care from Prevention to Survivorship of Hispanic Women: A Scoping Review. *J Racial Ethn Health Disparities*[3.2]. 2024 Aug; 11(4):1869-1887.

Sedrak MS, Sun CL, Bae M, Freedman RA, Magnuson A, O'Connor T, Moy B, Wildes TM, Klepin HD, Chapman AE[MONC], Tew WP, Dotan E, Fenton MA, Kim H, Katheria V, Muss HB, Cohen HJ, Gross CP, Ji J. Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study. *J Cancer Surviv*[3.1]. 2024 Aug; 18(4):1131-1143.



Swartz K, Chapman A[MONC], Zhan T, Wen KY[MONC]. Process evaluation of a G8 screening tool implementation in an outpatient oncology center. *J Geriatr Oncol*[3]. 2024 Jan; 15(1):101605.

Emiloju OE, Yin J, Koubek E, Reid JM, Borad MJ, Lou Y, Seetharam M, Edelman MJ, Sausville EA, Jiang Y, Kaseb AO, Posey JA[MONC], Davis SL, Gores GJ, Roberts LR, Takebe N, Schwartz GK, Hendrickson AEW, Kaufmann SH, Adjei AA, Hubbard JM, Costello BA. Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort. *Invest New Drugs*[3]. 2024 Feb; 42(1):127-135.

Beckermann KE, Patnaik A, Winer I, Tan W, Bashir B[MONC], Kyriakopoulos CE, Sweis RF, Chamberlain M, Rini BI. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. *Invest New Drugs*[3]. 2024 Apr; 42(2):179-184.

Lin D[MONC], Tan R, Teigland C, Hernandez S, Kim S, Kilgore KM. Race/ethnicity, and socioeconomic position in emergency department utilization in patients with hepatocellular carcinoma. *Future Oncol*[3]. 2024 Apr 19:1-13. [Epub ahead of print]

Kaur A, Streck B, Pergolotti M, Battisti NML, Krok-Schoen JL, Cabrera Chien L, Canin B, Ali I, Malone MV, MacKenzie A[MONC], Shahrokni A, Plotkin E, Boehmer LB, BrintzenhofeSzoc K. Cancer care physicians' attitudes toward do not resuscitate orders during the COVID-19 pandemic. *J Geriatr Oncol*[3]. 2024 May; 15(4):101717.


Nikita N[MONC], Gandhi K, Keith SW, Sharma S, Kelly WK[MONC], Lu-Yao G[MONC]. The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based study. *J Geriatr Oncol*[3]. 2024 Jun; 15(5):101773.

Hansen CL, Farber J, Binder A[MONC], Reist K, Brailovsky Y. Conversion of PYP/HMDP scanning on sequential imaging in a patient with a TTR gene mutation. *J Nucl Cardiol*[3]. 2024 Jul; 37:101780.

Dotan E, Lynch SM, Ryan JC, Mitchell EP[MONC]. Disparities in care of older adults of color with cancer: A narrative review. *Cancer Med*[2.9]. 2024 Feb; 13(3):e6790.

Patel JN, Jiang C, Owzar K, Hertz DL, Wang J, Mulkey FA, Kelly WK[MONC], Halabi S, Furukawa Y, Lassiter C, Dorsey SG, Friedman PN, Small EJ, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Ratain MJ, Morris MJ, McLeod HL. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). *Pharmacogenomics J*[2.9]. 2024 Mar 04; 24(2):6.

Myers RE[MONC], Hallman MH, Shimada A, DiCarlo MA, Davis KV, Leach WT, Chambers CV. Primary care patient interests in joining a planned multi-cancer early detection clinical trial. *Cancer Med*[2.9]. 2024 May; 13(10):e7312.



Quintanilha JCF, Kelly WK[MONC], Innocenti F. Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension. *Pharmacogenomics J*[2.9]. 2024 Jul 12; 24(4):22.

Blaes AH, Abu-Khalaf MM[MONC], Bender CM, Dent SF, Fung C, Smith SK, Watson S, Katta S, Merrill JK, Hudson SV. Coverage for evidence-based cancer survivorship care services. *Support Care Cancer*[2.8]. 2024 Feb 17; 32(3):165.

Elgohary G, Yang Y, Gergis M, Yi D, Gergis U[MONC]. Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis. *Clin Lymphoma Myeloma Leuk*[2.7]. 2024 Apr; 24(4):e142-e151.

Melillo RJ, El Khoury C, Shaver AL[MONC], Cunningham M, Benavides N, Lacerda Q, Kim FJ, Leader AE[MONC]. A student-community partnership to enhance cancer research training. *BMC Med Educ*[2.7]. 2024 Oct 17; 24(1):1164.

Lopez AM[MONC]. Telehealth in Cancer Care: Inequities, Barriers, and Opportunities. *Cancer J*[2.6]. 2024 Jan-Feb 01; 30(1):2-7.

Bittner Fagan H, Jurkovitz C, Zhang Z, Thompson LA, Patterson F, Zazzarino MA, Myers RE[MONC]. Primary care outreach and decision counseling for lung cancer screening. *J Med Screen*[2.6]. 2024 Sep; 31(3):150-156.


Mitchell E[MONC], Borum ML. Understanding the current status of respiratory illness in the United States. *J Natl Med Assoc*[2.5]. 2024 Feb; 116(1):2.

Binder AF[MONC], Hossain A, Doshi R, Vivero A, Gonzalez KM, Gentsch A, Wilde L[MONC], Rising KL. Patient and caregiver perceptions of the possibility of home blood transfusions. *Transfusion*[2.5]. 2024 Mar; 64(3):483-492.

Mitchell E[MONC], Comerford K, Knight M, McKinney K, Lawson Y. A review of dairy food intake for improving health among black geriatrics in the US. *J Natl Med Assoc*[2.5]. 2024 Apr; 116(2 Pt 2):274-291.

Lawson Y, Comerford KB, Mitchell EP[MONC]. A review of dairy food intake for improving health for black women in the US during pregnancy, fetal development, and lactation. *J Natl Med Assoc*[2.5]. 2024 Apr; 116(2 Pt 2):219-227.

Mitchell E[MONC], Comerford K, Knight M, McKinney K, Lawson Y. A review of dairy food intake for improving health among black adults in the US. *J Natl Med Assoc*[2.5]. 2024 Apr; 116(2 Pt 2):253-273.



Comerford K, Lawson Y, Young M, Knight M, McKinney K, Mpasi P, Mitchell E[MONC]. Executive summary: The role of dairy food intake for improving health among Black Americans across the life continuum. *J Natl Med Assoc*[2.5]. 2024 Apr; 116(2 Pt 2):211-218.

Comerford K, Lawson Y, Young M, Knight M, McKinney K, Mpasi P, Mitchell E[MONC]. The role of dairy food intake for improving health among black Americans across the life continuum: A summary of the evidence. *J Natl Med Assoc*[2.5]. 2024 Apr; 116(2 Pt 2):292-315.

Lawson Y, Mpasi P, Young M, Comerford K, Mitchell E[MONC]. A review of dairy food intake for improving health among black children and adolescents in the US. *J Natl Med Assoc*[2.5]. 2024 Apr; 116(2 Pt 2):241-252.

Lawson Y, Mpasi P, Young M, Comerford K, Mitchell E[MONC]. A review of dairy food intake for improving health among black infants, toddlers, and young children in the US. *J Natl Med Assoc*[2.5]. 2024 Apr; 116(2 Pt 2):228-240.

Katcher JG, Klassen AC, Hann HW, Chang M, Juon HS[MONC]. Racial discrimination, knowledge, and health outcomes: The mediating role of hepatitis B-related stigma among patients with chronic hepatitis B. *J Viral Hepat*[2.5]. 2024 May; 31(5):248-254.

Shusted CS, Eberth JM, Juon HS[MONC], Barta JA. Characteristics associated with early vs. late adoption of lung cancer screening. *Prev Med Rep*[2.4]. 2024 Aug; 44:102820.


Fleming S, Gifkins D, Resnick HE, Shalaby W, Rosenberg P, Gaj C, Maio V, Crawford A, Lu-Yao G[MONC], Gao J, Siefker-Radtke A. Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma. *Clin Genitourin Cancer*[2.3]. 2024 Jun; 22(3):102054.

Jeurkar C[MONC], Leiby B, Rashid S, Gergis U[MONC], Grossso D, Carabasi M, Filicko-O'Hara J[MONC], O'Hara W, Klumpp T, Porcu P[MONC], Flomenberg N, Wagner JL. A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher $\gamma\delta$ T cell dose. *Eur J Haematol*[2.3]. 2024 Sep; 113(3):283-289.

Wei S, Patchefsky AS, Pei J, Brown SA, Basu Mallick A[MONC], Wang Z, Jiang W. PHF1::TFE3-positive fibromyxoid sarcoma? Report of 2 cases and review of 13 cases of PHF1::TFE3-positive ossifying fibromyxoid tumor in the literature. *Am J Clin Pathol*[2.3]. 2024 Sep 09. [Epub ahead of print]

Braunstein Z, Waller A, Dotson E, McLaughlin E, Hanel W, Reneau J, Addison D, Porcu P[MONC], Brammer JE. Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas. *Leuk Lymphoma*[2.2]. 2024 Mar; 65(3):301-311.

Awaad R, Midani M, Ali T, Sifat MS[MONC], Albatnuni M. The Development and Implementation of a Custom-Tailored Suicide Response Training for Muslim Communities. *J Relig Health*[2.2]. 2024 Jun; 63(3):1954-1966.



Leader AE[MONC], Song Y, González ET, Fortune T, Graciani N, Zeigler-Johnson C, Glanz K. Developing a city-wide, community-engaged cancer disparities research agenda. *Cancer Causes Control*[2.2]. 2024 Sep 28. [Epub ahead of print]

Nelson NG, Burke SE, Cappelli L, Matlack LE, Smith AP, Francois N, Lombardo JF, Shah YB, Wen KY[MONC], Shafi AA, Simone NL. Temporal Considerations in Brain Metastases Radiation Therapy: The Intersection of Chronobiology and Patient Profiles. *Clocks Sleep*[2.1]. 2024 Mar 21; 6(1):200-210.

Majeed A, Alaparthi S, Haleboua-DeMarzio D, Eberle-Singh J, Jiang W, Anne PR, Shah AP, Bowne WB, Lin D[MONC]. Complete Pathologic Response to Gemcitabine and Oxaliplatin Chemotherapy After Prior Therapies in a Patient With Hepatocellular Carcinoma and Peritoneal Metastases Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *World J Oncol*[2.1]. 2024 Jun; 15(3):511-520.

Jeminiwa R, Park S, Popielaski C, Gannon M, Myers R[MONC], Abatemarco DJ. Development of an Educational Brochure about Treatment Options for Pregnant Women with Opioid Use Disorders. *Pharmacy (Basel)*[2]. 2024 Jun 22; 12(4).

Bloom MD, Bashir B[MONC]. Emerging role of circulating tumor DNA for early detection of recurrence in biliary tract cancers. *J Gastrointest Oncol*[2]. 2024 Jun 30; 15(3):1358-1362.


Booher A, Mao JJ, Muniz RC, Romero SAD, Li SQ, Lopez AM[MONC], Liou KT. Association between Hispanic Ethnicity and Greater Expectation of Benefit from Acupuncture or Massage for Pain in Cancer. *J Immigr Minor Health*[2]. 2024 Jul 08. [Epub ahead of print]

Paller CJ, Zahurak ML, Mandl A, Metri NA, Lalji A, Heath E, Kelly WK[MONC], Hoimes C, Barata P, Taksey J, Garrison DA, Patra K, Milne GL, Anders NM, Nauroth JM, Durham JN, Marshall CH, Markowski MC, Eisenberger MA, Antonarakis ES, Carducci MA, Denmeade SR, Levine M. High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial. *Cancer Res Commun*[2]. 2024 Aug 01; 4(8):2174-2182.

Poklepovic AS, Gordon SW[MONC], Kothadia S, McGuire WP, Thacker LR, Deng X, Tombes MB, Shrader E, Hudson D, Bandyopadhyay D, Ryan AA, Kmiecik M, Smith S, Dent P. A phase 1 study of regorafenib and sildenafil in adults with advanced solid tumors. *Anticancer Drugs*[1.8]. 2024 Jun 01; 35(5):450-458.

Rohan TZ, Suriano J, Tekmen V, Bhatti S, Talasila S, Joffe D, Holtmeyer C, Lee JB, Alpdogan O[MONC], Nikbakht N. Coexistence of large cell transformed mycosis fungoides and diffuse large B-cell lymphoma in one patient. *J Cutan Pathol*[1.6]. 2024 Jul 05. [Epub ahead of print]

Tucker M, Hovern D, Liantonio J, Collins E, Binder AF[MONC]. End of Life Outcomes Following Comfort Care Orders: A Single Center Experience. *Am J Hosp Palliat Care*[1.5]. 2024 May 13:10499091241253561. [Epub ahead of print]



Gleason L, Afifi L, Banner L, Talasila S, Joffe D, Bhatti S, Alpdogan O[MONC], Porcu P[MONC], Nikbakht N. Challenges in utilizing ALK expression to distinguish primary cutaneous from systemic anaplastic large cell lymphoma. *Mol Clin Oncol*[1.4]. 2024 May; 20(5):35.

Bao T, Lopez G, Crudup T, Lopez AM[MONC], Paller CJ, Gowin K, Mehta A, Witt CM, Zick SM, Balneaves LG. Advancing Integrative Oncology: The Society for Integrative Oncology Education Committee's Journey and Vision. *J Integr Complement Med*[1.3]. 2024 Aug 26. [Epub ahead of print]

Iskandar AS[MONC], Zarrabi KK[MONC], Tester WJ[MONC]. Renal cell carcinoma: entering the age of biomarkers. *Can J Urol*[1.2]. 2024 Aug; 31(4):11921-11930.

Kelly WK[MONC]. STEAP1 as a potential target for new therapies in prostate cancer. *Clin Adv Hematol Oncol*[1.1]. 2024 Jun; 22(5):243-244.

Christensen D, Belair JA, Basu-Mallick A[MONC], Brown SA, Klein M, Jiang W. Synchronous Low-Grade Central Osteosarcoma and Ewing Sarcoma: A Rare Case Report. *Int J Surg Pathol*[0.9]. 2024 Mar 20:10668969241239675. [Epub ahead of print]


Holder S, Sifat M[MONC], Kuo C, Green K. The Role of Adolescent Anxious Mood, Marijuana Use, and Locus of Control in the School to Prison Pipeline. *Educ Urban Soc*[0.8]. 2024 May; 56(4):472-492.

Joffe D, Rohan TZ, Mandel J, Suriano J, Banner L, Valiga A, Porcu P[MONC], Gong JZ, Lee JB, Alpdogan O[MONC], Nikbakht N. The development of 2 clonally and histologically distinct subtypes of extranodal B-cell lymphomas in the brain and skin in 1 individual. *JAAD Case Rep*[UK]. 2024 Jul; 49:51-54.

Ashare RL, Worster B, Nugent SM, Smith DM, Morasco BJ, Leader AE[MONC], Case AA, Meghani SH. Cannabis and opioid perceptions, co-use, and substitution among patients across 4 NCI-Designated Cancer Centers. *J Natl Cancer Inst Monogr*[UK]. 2024 Aug 15; 2024(66):267-274.

Jeminiwa R, Dadabaev F, Kim H, Gannon M, Myers R[MONC], Abatemarco DJ. Perspectives of physicians and doulas on shared decision-making and decision counseling in the treatment of pregnant women with opioid use disorders. *J Subst Use Addict Treat*[UK]. 2024 Sep 27:209526. [Epub ahead of print]

Mastrolonardo EV, Nunes KL, Llerena P, Nikitina A, Sobol A, Scott ER, Tuluc M, Davitt CJH, Scher J, Tekumalla S, Mann D, Henao C, Jegede V, Gargano S, Harshyne LA, Alnemri A, Tyshevich A, Kushnarev V, Chasse M, Sookiasian D, Axelrod R[MONC], Zhan T, Leiby BE, Old M, Seim N, Mahoney MG, Martinez-Outschoorn U[MONC], Cognetti DM, Curry JM, Prendergast G, Argiris A, South AP, Linnenbach AJ, Johnson JM[MONC], Luginbuhl AJ. Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma. *Clin Cancer Res*[10]. 2024 Nov 25. [Epub ahead of print]



Ruiz M, Braunstein Z, McLaughlin E, Mishra A[MONC], Porcu P[MONC], Brammer JE. Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia. *Haematologica*[8.2]. 2024 Nov 14. [Epub ahead of print]

Dimitriou F, Orloff MM[MONC], Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob JJ, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. *Eur J Cancer*[7.6]. 2024 Nov 30; 214:115161. [Epub ahead of print]

Spigel DR, Wang JS, Pronk L, Muskens B, Teufel M, Bashir B[MONC], Burris H. A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors. *ESMO Open*[7.1]. 2024 Nov; 9(11):103730.

Duong T, Hafer R, Yang HY, Tolotta J, Mandel JL, Banner L, Porcu P[MONC], Nikbakht N. The Risk of Developing Keratinocyte Malignancies in Patients with Cutaneous T-cell Lymphoma. *J Invest Dermatol*[5.7]. 2024 Dec 31. [Epub ahead of print]

DeCarli K, Bradbury A, Lopez AM[MONC], Camacho P, Chatwal MS, Frieze CR, Jimenez R, Johnson LM, McGuire AL, Spence R, Peppercorn J. Ethical and Clinical Considerations in Ordering and Responding to Molecular Diagnostics and Circulating Tumor DNA as the Science Evolves. *JCO Oncol Pract*[4.7]. 2024 Nov; 20(11):1508-1514.


Kendzor DE, Davie M, Chen M, Hart J, Frank-Pearce SG, Doescher MP, Alexander AC, Businelle MS, Ogunsanya M, Sifat MS[MONC], Boozary LK. Incentivizing Tobacco Helpline Engagement in Persistent Poverty Counties: A Randomized Trial. *Am J Prev Med* [4.3]. 2024 Oct 28. [Epub ahead of print]

Sifat MS[MONC], Kenney S, Bekteshi V, Chiang SC, Ogunsanya M, Boozary LK, Alexander AC, Kendzor DE. The association of migration-related stress with poor mental health among recently resettled Afghan refugees. *J Migr Health* [3.9]. 2024; 10:100282.

Lee G, Juon H[MONC], Kim E, Smith KC, Hann HW, Chang M, Klassen AC. HBV Transmission Knowledge Among Korean-American Chronic Hepatitis B Patients in the United States. *J Community Health* [3.9]. 2024 Nov 02. [Epub ahead of print]

Bradt J, Leader A[MONC], Worster B, Myers-Coffman K, Bryl K, Biondo J, Schneible B, Cottone C, Selvan P, Zhang F. Music Therapy for Pain Management for People With Advanced Cancer: A Randomized Controlled Trial. *Psychooncology*[3.3]. 2024 Oct; 33(10): e70005.

Kim HJ, Griffith KA, Ricciardi R, Le D, Glenn A, Cameron V, Juon HS[MONC]. Exploring disparities in healthcare utilization, cancer care experience, and beliefs about cancer among asian and hispanic cancer survivors. *Support Care Cancer* [2.8]. 2024 Oct 30; 32(11):756.



Shaikh AR, Lin D[MONC]. Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer? J Gastrointest Oncol [2]. 2024 Oct 31; 15(5):2343-2348.

Hochberg AR, Gomella PT, Im B, Ghosh A, Shah S, Thompson RAM, Zarrabi KK[MONC], Shah MS, Mark JR, Izes JK, Lallas CD, Gomella LG, Metwalli AR. Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel-Lindau? J Kidney Cancer VHL [1.9]. 2024; 11(4):28-38.

Melby G, Zeigler-Johnson C, Dicarlo M, Pham K, Shusted CS, Myers R[MONC]. Developing a Strategy to Increase Lung Cancer Screening in Areas of Need. Popul Health Manag [1.8]. 2024 Dec 20. [Epub ahead of print]

Ogunsanya ME, Frank-Pearce SG, Chen S, Sifat M[MONC], Cohn AM, Businelle MS, Kendzor DE. The influence of sociodemographic, tobacco use, and mental health characteristics on treatment adherence among adults enrolled in a community-based tobacco cessation program. Addict Behav Rep [UK]. 2024 Dec; 20:100568.

Waguespack SG, Cabanillas ME, Bernard-Gauthier V, Assar N, Bloom G, Esparza R, Brose MS[MONC]. A plain language summary looking at how well larotrectinib works and how safe it is for people with TRK fusion-positive thyroid cancer. Future Oncol [3]. 2024 Nov 29:1-12. [Epub ahead of print]

Shusted CS, Mukhtar S, Lee J, Ruane B, Muse E, Emeigh-McBride L, Gatson-Anderson E, Kane GC, Wen KY[MONC], Juon HS[MONC], Barta JA. Factors Associated With Receipt of Tobacco Treatment Integrated With Nurse Navigation in a Centralized Lung Cancer Screening Program at an Urban Academic Medical Center. Cancer Control [2.5]. 2024; 31:10732748241304966.

Regnault A, Bunod L, Loubert A, Brose MS[MONC], Hess LM, Maeda P, Lin Y, Speck RM, Gilligan AM, Payakachat N. Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. J Patient Rep Outcomes [2.4]. 2024 Dec 19; 8(1):149.

There were 155 publications authored by Medical Oncology Faculty Members from 1/1/24 to 12/31/24.

26 publications (16.77%) were intra-departmental collaborations(*).

Omitting Journals with an undefined Journal Impact Factor

22 publications (14.57%) had a Journal Impact Factor ≥ 10 (+).


26 publications (17.22%) had a Journal Impact Factor ≥ 9 (+ or ‡).

51 publications (33.77%) had a Journal Impact Factor ≥ 5 (+ or ‡ or #).


Average Journal Impact Factor [1050.3/151]: 6.96.

This list contains publications for the following Medical Oncology Faculty:


ABRAHAM, AID



ABU-KHALAF, MAYSА
ALPDOGAN, SEYFETTIN ONDER
ARGIRIS, ATHANASSIOS
ATIZ, MUHAMMAND UMAIR
AXELROD, RITA S.
BARSEVICK, ANDREA M.
BASHIR, BABAR
BASU MALLICK, ATRAYEE
BATRA, VIVEK
BHATIA, AVNISH K.
BHATTACHARYA, SAVERI
BHUTANI, SUCHIT
BINDER, ADAM
BISWAS, RAKESH
BI, XIA
BROSE, MARCIA
CAPPARELLI, CLAUDIA
CARABASI, MATTHEW H.
CHAKRAVARTI, NITIN
CHAPMAN, ANDREW E.
CHEN, JASON
COHEN, STEVEN J.
DOMINGO-DOMENECH, JOSEP
EL KHOURY, CHRISTIANE
EVANS, TRACEY L.
FELLIN, FREDERICK M.
FERBER, ANDRES
FILICKO-O'HARA, JOANNE E.
FLOMENBERG, NEAL
FNU, NIKITA
FRENCH, ZACHARY L.
GABALLA, SAMEH R.
GATTAS, BOULA
GERGIS, USAMA
GIRI, VEDA N.
GODWIN, JAMES LUKE
GORDON, SARAH W.
GROSSO, DOLORES
GROSSO, RACHAEL
HAFEZ, MARIA
HANDLEY, NATHAN R.
HOFFMAN-CENSITS, JEAN
IBIKUNLE, SIKEMI



ISKANDAR, ANDREW S.
JASLOW, REBECCA J.
JEURKAR, CHETAN
JOHNSON, JENNIFER M.
JUON, HEE-SOON
KASNER, MARGARET T.
KEIFFER, GINA
KELLY, WM. KEVIN
KIM, LYNDON K.
KLUMPP, THOMAS R.
LEADER, AMY E.
LIMONNIK, VLADMIR
LIN, DANIEL
LISS, ALISON
LIU, LING-ZHI
LOPEZ, ANA MARIA
LU, J. BYRON
LU-YAO, GRACE
MACKENZIE, AMY
MARTINEZ-OUTSCHOORN, UBALDO E.
MASTRANGELO, MICHAEL J.
MCNAIR, CHRISTOPHER
MICAILY, IDA
MILLE, PATRICK JOHNSTON
MISHRA, ANJALI
MITCHELL, EDITH P.
MOOKERJEE, BIJOYESH P.
MYERS, RONALD E.
NARDONE, EVAN
NEUPANE, MANISH
NIKITA, FNU
ORLOFF, MARLANA M.
PALMISIANO, NEIL D.
PAN, JONATHAN
PILLAI, MADHAVAN V.
PORCU, PIERLUIGI
POSEY, JAMES A.
RAMIREZ, MICHAEL J
RAZZO, BEATRICE M.
RODRIGUEZ, JOANNA
ROSE, LEWIS J.
SAMA, ASHWIN R.
SATO, TAKAMI



SCHILDER, RUSSELL J.
SEEDOR, RINO
SHARMA, MANISH
SHAVER, AMY L.
SIFAT, MUNJIREEN
SILVER, DANIEL P.
SINGLA, RAJAN
SKARIAH, SAM
TANEJA, ALANKRITA
TERAI, MIZUE
TESTER, WILLIAM J.
WAGNER, JOHN L.
WEAVER, EMMA
WEIGHT, RYAN
WEN, KUANG-YI
WILDE, LINDSAY
WILSON, MELISSA A.
WYSOTA, MICHAEL
YANG, HUSHAN
ZARRABI, KAYVAN
ZEIGLER-JOHNSON, CHARNITA M.
ZIBELLI, ALLISON M.
ZINNER, RALPH G.

